fluconazole has been researched along with Meningitis, Cryptococcal in 357 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Meningitis, Cryptococcal: Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection." | 7.69 | Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. ( Ammassari, A; Antinori, A; Linzalone, A; Marasca, G; Morace, G; Murri, R, 1995) |
| "We retrospectively analyzed clinical outcome of meningeal and extrameningeal cryptococcosis in HIV-negative patients treated with amphotericin B (43 patients) or fluconazole (40 patients)." | 7.69 | Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. ( Brugiere, O; Dromer, F; Dupont, B; Letenneur, L; Mathoulin, S, 1996) |
| "Treatment with 200 to 400 mg/day fluconazole was evaluated in 44 patients without AIDS who had cryptococcosis (19 with cryptococcal meningitis, 22 with pulmonary cryptococcosis, 3 with other cryptococcal infections)." | 7.69 | Fluconazole monotherapy for cryptococcosis in non-AIDS patients. ( Hara, K; Ikemoto, H; Ito, A; Kohno, S; Watanabe, K; Yamaguchi, H, 1996) |
| "Twenty-five patients had cryptococcal meningitis confirmed by culture, three had presumed cryptococcal meningitis, and three had disseminated extrameningeal cryptococcosis." | 6.68 | Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. ( de Lalla, F; Fabris, P; Franzetti, M; Manfrin, V; Pellizzer, G; Stecca, C; Vaglia, A, 1995) |
| "After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse." | 6.67 | A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. ( Cloud, GA; Follansbee, SE; Graybill, JR; Jacobson, JM; McAuliffe, VJ; Meyer, RD; Powderly, WG; Robinson, P; Saag, MS; Sugar, AM, 1992) |
| "The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines." | 5.69 | How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? ( Boulware, DR; Harrison, TS; Hosseinipour, MC; Jarvis, JN; Lawrence, DS; Lortholary, O; Meintjes, G; Mosepele, M; Mwandumba, HC, 2023) |
| "The combined infection of Actinomyces odontolyticus sepsis and cryptococcal encephalitis is first reported in this case report, and combined antibiotics with 'penicillin, amphotericin, and fluconazole' are effective." | 5.41 | Cryptococcal meningoencephalitis with Actinomyces odontolyticus sepsis: a case report and literature review. ( Hong, Q; Hong, Z; Huang, Q, 2023) |
| "Miltefosine treatment (1." | 5.39 | Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. ( Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Sorrell, TC; Wiederhold, NP, 2013) |
| "Fluconazole was discontinued at this time, and liposomal amphotericin B was resumed." | 5.35 | Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. ( Grayson, ML; McMahon, JH, 2008) |
| "Fluconazole is a commonly prescribed antifungal agent with a favorable safety profile." | 5.31 | Fluconazole-induced agranulocytosis with eosinophilia. ( Shriner, K; Wong-Beringer, A, 2000) |
| "Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) is particularly common in tropical Africa." | 5.28 | Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) in African patients: treatment with fluconazole. ( Aubry, P; Bogaerts, J; Dupont, B; Durbec, JP; Kadio, A; Laroche, R; Latif, A; M'Pele, P; Taelman, H; Touze, JE, 1992) |
| "Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia." | 5.20 | Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. ( Achan, B; Akampurira, A; Alhadab, AA; Boulware, DR; Hullsiek, KH; McDonald, TR; Meya, DB; Nielsen, K; Okagaki, LH; Rhein, JR; Smith, KD, 2015) |
| "Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. ( Cloud, GA; Fisher, JF; Grieco, MH; Powderly, WG; Robinson, P; Saag, MS; Sharkey, PK; Sugar, AM; Thompson, SE; Tuazon, CU, 1992) |
| " Five were exposed to 200-800 mg fluconazole during pregnancy." | 5.05 | Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. ( Boulware, DR; Evans, EE; Meya, DB; Muzoora, C; Nalintya, E; Ndyetukira, JF; Nuwagira, E; Pastick, KA; Rajasingham, R; Rhein, J; Skipper, C; Ssebambulidde, K; Stephens, N; Tugume, L, 2020) |
| "The clinical use of fluconazole in dosages > or = 800 mg/day has been reported in about 900 patients against candidemia, oropharyngeal candidiasis and cryptococcal meningitis in HIV-infected patients as well as for initial therapy of endemic mycoses." | 4.79 | [High-dose therapy with fluconazole > or = 800 mg/day. Review]. ( Penk, A; Pittrow, L, 1997) |
| "HIV-uninfected CM patients who received high-dose fluconazole (800 mg/d) for initial therapy in Huashan Hospital were included in this retrospective study from January 2013 to December 2018." | 4.31 | Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not? ( Cheng, JH; Jiang, YK; Luo, Y; Wang, X; Zhao, HZ; Zhou, LH; Zhu, LP; Zhu, RS, 2023) |
| " We present a case of cryptococcal meningitis in a renal transplant recipient presenting as acute sinusitis with successful treatment using fluconazole as primary therapy." | 3.79 | Cryptococcal meningitis presenting as sinusitis in a renal transplant recipient. ( Alangaden, G; Carron, M; Chandrasekar, P; Iyer, SP; Movva, K; Revankar, SG; Tranchida, P; Wiebel, M, 2013) |
| "In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection." | 3.69 | Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. ( Ammassari, A; Antinori, A; Linzalone, A; Marasca, G; Morace, G; Murri, R, 1995) |
| "We retrospectively analyzed clinical outcome of meningeal and extrameningeal cryptococcosis in HIV-negative patients treated with amphotericin B (43 patients) or fluconazole (40 patients)." | 3.69 | Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. ( Brugiere, O; Dromer, F; Dupont, B; Letenneur, L; Mathoulin, S, 1996) |
| "A case of acquired immunodeficiency syndrome (AIDS) developed cryptococcosis which was successfully treated with amphotericin B (AMPH) and fluconazole (FLCZ) is reported." | 3.69 | [A case of acquired immunodeficiency syndrome associated with cryptococcemia and cryptococcal meningitis]. ( Hashimoto, S; Horie, T; Inami, T; Nakayama, T; Nishinarita, S; Tomita, Y, 1996) |
| "Treatment with 200 to 400 mg/day fluconazole was evaluated in 44 patients without AIDS who had cryptococcosis (19 with cryptococcal meningitis, 22 with pulmonary cryptococcosis, 3 with other cryptococcal infections)." | 3.69 | Fluconazole monotherapy for cryptococcosis in non-AIDS patients. ( Hara, K; Ikemoto, H; Ito, A; Kohno, S; Watanabe, K; Yamaguchi, H, 1996) |
| " With the exception of a higher incidence of gastrointestinal side effects in the 2000mg cohort, both induction doses of FCZ were safe and well tolerated." | 3.30 | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS ( Aberg, JA; Badal-Faesen, S; Bukuru, A; Clifford, DB; Hogg, E; Komarow, L; Lagat, D; Lalloo, UG; Langat, D; Larsen, RA; Mave, V; McKhann, A; Pillay, S; Samaneka, W; Supparatpinyo, K; Ticona, E, 2023) |
| "Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa." | 3.11 | Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. ( Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Harrison, TS; Hlupeni, A; Hope, W; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kagimu, E; Kanyama, C; Kasibante, J; Lalloo, DG; Lawrence, DS; Leeme, T; Lortholary, O; Loyse, A; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Mpoza, E; Mutata, C; Muzoora, C; Mwandumba, HC; Mzinganjira, H; Ndhlovu, CE; Nuwagira, E; Rhein, J; Rutakingirwa, MK; Schutz, C; Siamisang, K; Singh, A; Ssebambulidde, K; Tugume, L; van Widenfelt, E; Wang, D; Youssouf, N, 2022) |
| " Participants received standard care - amphotericin combined with fluconazole for the first 2 weeks - or standard care plus tamoxifen 300 mg/day." | 3.01 | An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis. ( Beardsley, J; Binh, TQ; Chau, NVV; Day, JN; Geskus, R; Hope, W; Hung, LQ; Kestelyn, E; Krysan, D; Lalloo, DG; Lan, NPH; Mai, NTH; Ngan, NTT; Phu, NH; Tai, LTH; Thanh Hoang Le, N; Thwaites, GE; Trieu, PH; Tung, NLN; Van Anh, D; Van, NTT; Vi Vi, NN; White, NJ, 2021) |
| "Sertraline was associated with excess SAEs of psychosis." | 2.94 | Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. ( Bangdiwala, AS; Boulware, DR; Hullsiek, KH; Kirumira, P; Meya, DB; Nalintya, E; Naluyima, R; Namanda, S; Nikweri, Y; Rajasingham, R; Rutakingirwa, MK; Skipper, CP; Turya, F, 2020) |
| "Mortality was associated with Glasgow coma score (GCS) below 15 (adjusted Hazard ratio (aHR) 1." | 2.94 | Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda. ( Anywaine, Z; Day, J; Ggayi, AB; Kaleebu, P; Kibengo, FM; Kitonsa, J; Kiwanuka, J; Mayanja, Y; Nikweri, Y; Nsubuga, R; Onyango, M, 2020) |
| "Cryptococcal meningitis is a devastating brain infection cause by encapsulated yeasts of the Cryptococcus genus." | 2.82 | Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going? ( Day, JN; Flower, B; Ngan, NTT, 2022) |
| "High fluconazole dosage (800 mg/day) for the treatment of HIV-associated cryptococcal meningitis was associated with high serum and CSF fluconazole concentration." | 2.75 | Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. ( Andes, D; Anekthananon, T; Chetchotisakd, P; Filler, SG; Larsen, RA; Manosuthi, W; Nolen, TL; Pappas, PG; Sungkanuparph, S; Supparatpinyo, K; Wallace, D, 2010) |
| " Fluconazole at a dosage of 1200 mg per day is more fungicidal than at a dosage of 800 mg per day, but mortality rates remain unacceptably high." | 2.75 | Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. ( Harrison, TS; Hosseinipour, MC; Jackson, A; Jaffar, S; Jarvis, JN; Kamwendo, D; Kanyemba, C; Kenala, J; Namarika, D; Nussbaum, JC; Phulusa, J; van der Horst, CM, 2010) |
| "BACKGROUND." | 2.75 | Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. ( Gona, P; Hakim, JG; Kurangwa, M; Makadzange, AT; Ndhlovu, CE; Reid, M; Takarinda, K, 2010) |
| "7 mg/kg plus fluconazole 800 mg (the high-dosage combination) administered daily for 14 days, followed by fluconazole alone at the randomized dosage (400 or 800 mg per day) for 56 days." | 2.74 | A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. ( Anekthananon, T; Chetchotisakd, P; Filler, SG; Johnson, P; Kendrick, AS; Larsen, RA; Manosuthi, W; Morris, MI; Nolen, TL; Pappas, PG; Sobel, JD; Sungkanuparph, S; Supparatpinyo, K; Zimmer, LO, 2009) |
| " We conducted a prospective phase II dose escalation study employing doses of fluconazole ranging from 800 to 2000 mg daily for 10 weeks used alone or combined with flucytosine at 100 mg/kg per day for the first 4 weeks." | 2.73 | Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. ( Bozzette, SA; Haubrich, R; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Milefchik, E; Tilles, JG, 2008) |
| "Amphotericin B treatment in cryptococcosis requires daily hospital visits or admission." | 2.72 | Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. ( Boonpokbn, L; Maek-a-Nantawat, W; Mctm, AG; Phonrat, B; Pitisuttithum, P; Tansuphaswadikul, S, 2006) |
| "Cryptococcal meningitis is one of the major complications affecting the central nervous system of patients suffering from AIDS." | 2.71 | The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. ( Anunnatsiri, S; Chetchotisakd, P; Choksawadphinyo, K; Mootsikapun, P, 2003) |
| " Blood samples were collected from the first 12 patients in each group and pharmacokinetic parameters for fluconazole were calculated." | 2.71 | Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS. ( Panomvana Na Ayudhya, D; Tansuphaswadikul, S; Thanompuangseree, N, 2004) |
| "PCR as a rapid diagnostic tool for cryptococcal meningitis was evaluated." | 2.70 | Cryptococcal meningitis in AIDS. ( Banker, DD; Iyer, RS, 2002) |
| "Twenty-five patients had cryptococcal meningitis confirmed by culture, three had presumed cryptococcal meningitis, and three had disseminated extrameningeal cryptococcosis." | 2.68 | Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. ( de Lalla, F; Fabris, P; Franzetti, M; Manfrin, V; Pellizzer, G; Stecca, C; Vaglia, A, 1995) |
| " These results suggest that rifampicin dosage adjustment may not be necessary when this drug is coadministered with fluconazole." | 2.68 | Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients. ( Jaruratanasirikul, S; Kleepkaew, A, 1996) |
| "HIV-infected patients with cryptococcal meningitis were randomized to treatment with either liposomal amphotericin B (AmBisome) 4 mg/kg daily or standard amphotericin B 0." | 2.68 | Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. ( Allworth, T; Borleffs, JC; Clezy, K; de Marie, S; Hop, WC; Hoy, J; Jones, P; Kauffmann, RH; Kroon, FP; Leenders, AC; Portegies, P; Reiss, P; Verbrugh, HA, 1997) |
| " We conducted a prospective, open-label clinical trial involving persons with AIDS to determine whether the rate of clinical success would improve when fluconazole (400 mg daily) was combined with flucytosine (150 mg/kg daily)." | 2.67 | Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. ( Bauer, M; Bozzette, SA; Forthal, D; Haghighat, D; Jones, BE; Larsen, RA; Leal, MA; Leedom, JM; McCutchan, JA; Tilles, JG, 1994) |
| "After primary treatment for cryptococcal meningitis, patients with the acquired immunodeficiency syndrome (AIDS) require some form of continued suppressive therapy to prevent relapse." | 2.67 | A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. ( Cloud, GA; Follansbee, SE; Graybill, JR; Jacobson, JM; McAuliffe, VJ; Meyer, RD; Powderly, WG; Robinson, P; Saag, MS; Sugar, AM, 1992) |
| "The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made." | 2.61 | Recent advances in managing HIV-associated cryptococcal meningitis. ( Alanio, A; Boyer-Chammard, T; Harrison, TS; Jarvis, JN; Lortholary, O; Temfack, E, 2019) |
| "Mean fluconazole resistance was 10." | 2.58 | A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. ( Bongomin, F; Gago, S; Moore, CB; Oladele, RO; Richardson, MD, 2018) |
| "Two trials treated cryptococcal meningitis with amphotericin B and fluconazole; a third trial used fluconazole monotherapy; and the fourth trial did not specify the antifungal used." | 2.58 | Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. ( Bicanic, T; Eshun-Wilson, I; Okwen, MP; Richardson, M, 2018) |
| "Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of HIV-related deaths worldwide." | 2.58 | Treatment for HIV-associated cryptococcal meningitis. ( Eshun-Wilson, I; Ford, N; Jarvis, JN; Li, T; Rouse, B; Shapiro, AE; Tenforde, MW, 2018) |
| "For persons with symptomatic cryptococcal meningitis, optimal initial management with amphotericin and flucytosine improves survival compared to alternative therapies; however, amphotsericin is difficult to administer and flucytosine has not been available in middle or low income countries, where cryptococcal meningitis is most prevalent." | 2.55 | Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. ( Abassi, M; Boulware, DR; Lofgren, S; Rhein, J, 2017) |
| "Symptoms of cryptococcal meningitis are non-specific: headache, fever, nausea, or altered mental state and behaviour." | 2.52 | [Cryptococcal meningitis]. ( Aliredjo, RP; de Jong, PY; de Sévaux, RG; Nooijen, S; van Spil, WE; Verhave, JC, 2015) |
| " The objective of this study was to compare the survival benefit between 5-FC (flucytosine) and fluconazole as second-line drugs given in combination with AmB." | 2.50 | Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. ( Lin, DF; Lu, X; Shen, C; Yao, ZW, 2014) |
| "Amphotericin B based treatment is appropriate where possible." | 2.45 | Treatment of cryptococcal meningitis in resource limited settings. ( Dedicoat, MJ; Lalloo, DG; Sloan, DJ, 2009) |
| " The optimal dosing of AmB remains unclear." | 2.44 | Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. ( Dedicoat, M; Dlamini, S; Paul, N; Sloan, D, 2008) |
| "The IRIS presentation was lymphadenitis in all three patients; one patient also had meningeal IRIS." | 2.43 | Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. ( Hardy, RD; Hester, LJ; Skiest, DJ, 2005) |
| "The most common causes of cerebral infarction in AIDS are central nervous system infections: toxoplasmosis, cryptococcal meningitis and tuberculosis." | 2.42 | Cerebral infarction related to cryptococcal meningitis in an HIV-infected patient: case report and literature review. ( Bonasser Filho, F; Leite, AG; Nogueira, RS; Oliveira, AC; Vidal, JE, 2004) |
| "Cryptococcal meningitis is a common opportunistic infection in AIDS patients, particularly in Southeast Asia and Africa." | 2.42 | Cryptococcal meningitis. ( Bicanic, T; Harrison, TS, 2004) |
| "Sarcoidosis is an independent risk factor for cryptococcal infection; most patients with sarcoidosis who develop cryptococcal infection are not on immunosuppressive drugs." | 2.41 | Cryptococcal meningitis and sarcoidosis. ( Katz, JD; Ross, JJ, 2002) |
| "Fluconazole is an effective treatment for cryptococcal meningitis." | 2.39 | The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. ( Cartledge, J; Fisher, M; Gazzard, BG; Nelson, MR; Rogers, T, 1994) |
| "In patients with AIDS with cryptococcosis, prompt diagnosis is essential." | 2.39 | Management of systemic manifestations of fungal disease in patients with AIDS. ( Stevens, DA, 1994) |
| "The optimum regimen for the treatment of cryptococcal meningitis in patients with AIDS is still not totally clear." | 2.39 | Recent advances in the management of cryptococcal meningitis in patients with AIDS. ( Powderly, WG, 1996) |
| "Cryptococcal meningitis is a difficult disease to treat and requires biochemical and haematological monitoring to detect the common adverse effects of treatment." | 2.39 | The management of cryptococcal meningitis in Papua New Guinea. ( Seaton, RA, 1996) |
| "In the U." | 2.38 | Cryptococcal meningitis in patients with AIDS. ( Mocsny, N, 1992) |
| "Treatment of cryptococcal meningitis in patients with AIDS with amphotericin B plus flucytosine is associated with a failure rate of 20%-30%." | 2.38 | Therapy for cryptococcal meningitis in patients with AIDS. ( Powderly, WG, 1992) |
| " The objective of the study was to investigate the efficacy of acetazolamide (AZA), candesartan (CAN), and triciribine (TCBN), in combination with the antifungal fluconazole, on C." | 1.91 | A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis. ( Alanazi, AH; Chastain, DB; Franco-Paredes, C; Henao-Martínez, AF; Lin, X; Narayanan, SP; Parvathagiri, V; Rudraraju, M; Shan, S; Somanath, PR, 2023) |
| "Treatment of life-threatening cryptococcal meningitis (CM) is highly challenging due to the limited efficacy of the available antifungal drugs." | 1.72 | Discovery of Novel Sertraline Derivatives as Potent Anti- ( Ji, C; Li, J; Li, W; Liu, N; Sheng, C; Tu, J; Yang, W; Yun, Z, 2022) |
| "Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit." | 1.72 | Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. ( Black, J; Boretti, L; Garcia, A; Govender, NP; Greene, GS; Harrison, TS; Madua, M; Mashau, RC; Meintjes, G; Meiring, ST; Menezes, C; Nel, J; Quan, VC; Reddy, DL; Shroufi, A; Stacey, S; Trivino-Duran, L; Venter, M, 2022) |
| "Our previous study explored Amphotericin B (AMB) plus 5-flucytosine (5-FC) combined with fluconazole (FLU) therapy in the induction period, which seemed to be better than the previous AMB + 5-FC antifungal therapy in non-HIV and non-transplant-associated CM." | 1.72 | Amphotericin B plus fluorocytosine combined with voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study. ( Jiang, Y; Li, M; Liu, J; Peng, F; Su, X; Wang, A; Wang, Y; Xu, X; Yang, L, 2022) |
| " Laboratory adverse events (grade 3 or 4), such as severe anemia, were less frequent with VCZ + 5FC use than with AmB-D combined with 5FC or Flu use." | 1.72 | Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China. ( Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022) |
| "Neuromeningeal cryptococcosis and pulmonary tuberculosis are respectively serious mycotic and bacterial infections occurring in a subject regardless of its HIV serological status." | 1.72 | [Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali]. ( Alle Akakpo, AE; Cissoko, Y; Dao, S; Konaté, I; Loua, OO; Ouedraogo, D; Soumaré, M, 2022) |
| "Treatment with fluconazole is only recommended for localised pulmonary disease." | 1.62 | Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease. ( Larson, L; Mejia-Chew, C; Powderly, WG; Spec, A; Sung, A, 2021) |
| "He had multiple prior episodes of cryptococcal meningitis with complications necessitating ventriculoperitoneal shunt placement and was on suppressive fluconazole when he developed worsening brain manifestations." | 1.56 | Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. ( Jeng, A; Kalinoski, T; Malenfant, J; Yim, C, 2020) |
| " In fact, certain drugs may interact in ways that make treatment less effective." | 1.56 | Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. ( Ayala, M; Brammer, B; Brown, JC; Denham, ST; Stonhill, MA; Wambaugh, MA, 2020) |
| "Cryptococcal meningitis is a fungal infection that is most commonly thought of as an opportunistic infection affecting immunocompromised patients, classically patients with Human Immunodeficiency (HIV) infection." | 1.56 | Cryptococcal meningitis in an immunocompetent patient. ( Lacy, AJ; Murphy, LS; Shah, KS; Smith, AT, 2020) |
| "Triple antifungal agents combined with VPS could effectively reduce ICP, had faster rate of clearance of C." | 1.56 | Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure. ( Deng, X; Gan, Q; Jiang, Y; Li, M; Liu, J; Peng, F; Wang, Y; Xu, X, 2020) |
| "Mortality from cryptococcal meningitis remains very high in Africa." | 1.56 | Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis. ( Chan, AK; Chanda, D; Chen, T; Harrison, TS; Heyderman, RS; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Kanyama, C; Kivuyo, S; Kouanfack, C; Lakhi, S; Lortholary, O; Loyse, A; Mfinanga, S; Molloy, SF; Mwaba, P; Mwenge, L; Niessen, LW; Shiri, T; Temfack, E, 2020) |
| "Postmortem cryptococcal meningitis and pulmonary cryptococcosis were identified at MIA in all 4 CrAg-positive participants, 3 of whom had negative cerebrospinal fluid CrAg tests from lumbar punctures (LPs) at the time of CrAg screening." | 1.56 | Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. ( Govender, NP; Harrison, TS; Ismail, NA; Jarvis, JN; Karat, AS; Mazanderani, AH; Nel, C; Omar, T; Tiemessen, CT; Wake, RM, 2020) |
| "Clinical treatment of cryptococcal meningitis (CM) remains a significant challenge because of the lack of effective and safe drug therapies." | 1.51 | Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis. ( Han, G; Ji, C; Jiang, Y; Li, Z; Liu, N; Sheng, C; Tu, J; Wang, Y, 2019) |
| "Amphotericin B was used in 13 patients." | 1.51 | [Forty cases of neuromeningeal cryptococcosis diagnosed at the Mycology-Parasitology Department of the Ibn Sina hospital in Rabat, over a 21-year period]. ( Aoufi, S; Bandadi, FZ; Lyagoubi, M; Moustachi, A; Raiss, C, 2019) |
| "The present study showed that mixed infections exist and could be of particular importance for care outcomes." | 1.51 | Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. ( Bellet, V; Bertout, S; Chabrol, A; Delaporte, E; Doumbia, A; Drakulovski, P; Kakou, A; Kassi, FK; Krasteva, D; Landman, R; Menan, HEI; Reynes, J; Roger, F, 2019) |
| "She was diagnosed with cryptococcal meningitis in diabetes and had a remarkable response to fluconazole monotherapy." | 1.51 | CRYPTOCOCCAL meningitis in a HIV negative newly diagnosed diabetic patient: a CASE report. ( Chege, P; Owuor, OH, 2019) |
| "Cryptococcal meningitis is an opportunistic infection predominantly affecting immunocompromised patients but rarely can affect the immunocompetent." | 1.51 | Rare presentation of cryptococcal meningitis in an immunocompetent patient. ( Khattab, A; Patruni, S; Sealey, ML, 2019) |
| "Cryptococcal meningitis has fatality rates of 40%-70%, resulting in 200 000 deaths each year." | 1.51 | The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans. ( Day, JN; Hai, TP; Krysan, D; Lan, NPH; Ngan, NTT; Nhat, LTH; Thwaites, GE; Van, AD; Vinh Chau, NV, 2019) |
| "Cryptococcal meningitis has a high morbidity and mortality among AIDS population." | 1.51 | Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil. ( Borges, MASB; de Araújo Filho, JA; de Bastos, AL; de Paula, VV; Moreira, IS; Oliveira, BJS; Soares, RBA; Turchi, MD, 2019) |
| "BACKGROUND Cryptococcal meningitis in patients who are seronegative for the human immunodeficiency virus (HIV) and in patients who are splenectomized is rare." | 1.48 | A Rare Presentation of Cryptococcal Meningitis and Cerebellitis in an Asplenic Patient, Seronegative for Human Immunodeficiency Virus (HIV). ( Abbas, H; Abbas, N; CiFuentes Kottkamp, A; Cindrich, R; Singh, M, 2018) |
| "Most had confirmed cryptococcal meningitis, and 54% (14/26) of the symptomatic CrAg+ persons were dead or lost at 6 months." | 1.48 | A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. ( Boulware, DR; Huppler Hullsiek, K; Lofgren, S; Meya, DB; Nalintya, E; Rajasingham, R, 2018) |
| "Stroke is an increasing cause of morbidity and mortality amongst HIV infected persons." | 1.48 | Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. ( Benjamin, LA; Ellis, JP; Harrison, TS; Heyderman, RS; Joekes, EC; Kalata, N; Kampondeni, S; Lalloo, DG, 2018) |
| "Cryptococcal meningitis is one of the leading causes of death in HIV/AIDS patients." | 1.46 | Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain. ( Alastruey-Izquierdo, A; Aller, AI; Cuesta, I; Gago, S; Gómez-López, A; Martín-Mazuelos, E; Mellado, E; Serrano, C, 2017) |
| "Fluconazole 1200mg was prescribed to 29 (63%) patients." | 1.46 | [Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast]. ( Doumbia, A; Eholié, SP; Ehui, E; Ello, NF; Kassi, FK; Kassi, NA; Keita, M; Kouakou, GA; Mossou, C; Tanon, A, 2017) |
| "We describe a patient with systemic lupus erythematosus diagnosed with simultaneous cryptococcal and TB meningitis who had a poor response to intravenous liposomal amphotericin B and fluconazole, but was successfully treated with intraventricular amphotericin B, in addition to anti-TB therapy." | 1.43 | Simultaneous cryptococcal and tuberculous meningitis in a patient with systemic lupus erythematosus. ( Arslan, F; Mert, A; Mete, B; Ozaras, R; Ozkara, C; Ozturk, R; Saltoglu, N; Tabak, F; Vanli, E, 2016) |
| "Cryptococcosis is a potentially severe infection that usually occurs in a setting of immunosuppression." | 1.43 | [Multiple facial nodules revealing disseminated cryptococcosis in an immunocompetent patient]. ( Benzekri, A; Benzekri, L; Hassam, B; Ismaili, N; Lyagoubi, M; Mansouri, S; Rachadi, H; Ramli, I; Senouci, K, 2016) |
| "In the United States, cryptococcal meningitis causes approximately 3400 hospitalizations and approximately 330 deaths annually." | 1.43 | Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. ( Boulware, DR; Merry, M, 2016) |
| "Cryptococcal meningitis is a mycosis encountered especially in patients with Acquired Immunodeficiency Syndrome and is fatal in the absence of treatment." | 1.42 | Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole. ( Bertout, S; Boyom, FF; Delaporte, E; Dongtsa, J; Fomena, S; Kammalac Ngouana, T; Kouanfack, C; Mallié, M; Tonfack, C, 2015) |
| "Our case challenges the concept that immune reconstitution inflammatory syndrome and microbiological relapse are dichotomous entities." | 1.42 | Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. ( Arastéh, K; Blechschmidt, C; Boulware, DR; Branding, G; Katchanov, J; Meintjes, G; Nielsen, K; Stocker, H; Tintelnot, K, 2015) |
| "The fluconazole treatment was changed to liposomal amphotericin-B and flucytosine after the diagnosis of cryptococcal meningitis." | 1.40 | Pulmonary cryptococcosis with endobronchial lesions and meningitis. ( Ishiguro, T; Odashima, K; Shimizu, Y; Sugita, Y; Takayanagi, N, 2014) |
| " Fluconazole may be an inferior agent for induction therapy because many patients cannot achieve the pharmacodynamic target." | 1.39 | Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. ( Al-Nakeeb, Z; Felton, TW; Goodwin, J; Gregson, L; Harrison, TS; Hope, WW; Howard, SJ; Livermore, J; Perfect, JR; Sharp, A; Sudan, A; Warn, PA, 2013) |
| " Fluconazole monotherapy is frequently recommended in national guidelines but is a fungistatic drug compromised by uncertainty over optimal dosing and a paucity of clinical end-point outcome data." | 1.39 | A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. ( Allain, T; Chikafa, J; Denis, B; Feasey, NA; Goodson, P; Harrison, T; Heyderman, RS; Lalloo, DG; Mukaka, M; Rothe, C; Sloan, DJ; van Oosterhout, JJ, 2013) |
| "Miltefosine treatment (1." | 1.39 | Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis. ( Bocanegra, R; Kirkpatrick, WR; Najvar, LK; Patterson, TF; Sorrell, TC; Wiederhold, NP, 2013) |
| "Immunocompetent children with cryptococcal meningitis who attended Changzheng Hospital between 1998 and 2007 were retrospectively reviewed." | 1.38 | Cryptococcal meningitis in immunocompetent children. ( Hai, W; Jianghan, C; Julin, G; Nan, X; Wanqing, L; Xiaojun, W; Yuanjie, Z, 2012) |
| "Cryptococcal meningitis has emerged as a leading cause of infectious morbidity and mortality in patients with AIDS." | 1.38 | A retrospective study of AIDS-associated cryptomeningitis. ( Chakrabarti, A; Randev, S; Sachdeva, RK; Sharma, A; Singh, S; Varma, S; Wanchu, A, 2012) |
| "In many resource-limited settings, cryptococcal meningitis (CM) contributes up to 20% of all deaths with further complications due to Immune Reconstitution Inflammatory Syndrome (IRIS)." | 1.38 | Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. ( Bohjanen, P; Lukande, R; Mayanja-Kizza, H; Meya, BD; Musubire, AK; R Boulware, RD; Wiesner, LD, 2012) |
| "Of 46 patients with cryptococcal meningitis identified, 21 were cured after 10 weeks of treatment." | 1.38 | Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. ( Chang, TY; Chen, FJ; Chien, CC; Lee, CH; Liu, JW; Lu, CH; Tang, YF, 2012) |
| "The patient with cryptococcal meningitis was treated with amphotericin B and fluconazole and the patient with cerebral aspergilloma with voriconazole." | 1.38 | Two rare cases of central nervous system opportunistic mycoses. ( Baršić, B; Mlinarić Missoni, E, 2012) |
| "Cryptococcal meningitis is much less common in children than adults." | 1.37 | [Cryptococcal meningitis in children: description of 3 cases]. ( Diagne, NR; Diop, AG; Ndiaye, M; Ndiaye, MM; Seck, LB; Sène, MS; Sow, AD; Sow, HD, 2011) |
| "Cryptococcal meningitis is the most common life-threatening fungal infection and is associated with high mortality in children." | 1.36 | The role of an Ommaya reservoir in the management of children with cryptococcal meningitis. ( Gao, F; Jiang, PF; Shen, SX; Shui, QX; Xia, ZZ; Yu, HM; Zhou, BL, 2010) |
| "Cryptococcal meningitis is the commonest cause of adult meningitis in Southern Africa." | 1.36 | Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. ( Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Williams, Z, 2010) |
| "Cryptococcosis is a rare infection with high mortality in patients who have undergone heart transplantation (HT)." | 1.35 | Review of risk factors in four cases of cryptococcosis after heart transplantation. ( Chen, YS; Chi, NH; Chou, NK; Tsai, HE; Wang, JL; Wang, SS, 2008) |
| "Therapy for human immunodeficiency virus (HIV)-associated cryptococcal meningitis in many centers in Africa is fluconazole administered at a dosage of 400-800 mg per day." | 1.35 | Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. ( Andia, I; Chakera, A; Harrison, TS; Jaffar, S; Longley, N; Muzoora, C; Mwesigye, J; Rwebembera, J; Taseera, K; Wall, E, 2008) |
| "Two HIV-infected patients had recurrent cryptococcal meningitis (CM) despite treatment with fluconazole and immune reconstitution with combination antiretroviral therapy (CART)." | 1.35 | Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution. ( Corbett, EL; Ferrand, RA; Mangeya, N; Miller, RF; Seddon, J, 2009) |
| "Progress in therapy for cryptococcal meningitis has been slow because of the lack of a suitable marker of treatment response." | 1.35 | Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. ( Bekker, LG; Bicanic, T; Brouwer, AE; Chierakul, W; Harrison, TS; Jaffar, S; Jarvis, J; Limmathurotsakul, D; Longley, N; Loyse, A; Meintjes, G; Muzoora, C; Rebe, K; Stepniewska, K; Taseera, K; White, NJ; Wood, R, 2009) |
| "Of 101 AIDS patients with cryptococcal meningitis who received highly active antiretroviral therapy (HAART), 13 experienced cryptococcal IRIS." | 1.35 | Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. ( Anekthananon, T; Chetchotisakd, P; Filler, SG; Johnson, PC; Kendrick, AS; Kopetskie, H; Larsen, RA; Manosuthi, W; Morris, MI; Nolen, TL; Pappas, PG; Sobel, JD; Sungkanuparph, S; Supparatpinyo, K, 2009) |
| "Fluconazole was discontinued at this time, and liposomal amphotericin B was resumed." | 1.35 | Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. ( Grayson, ML; McMahon, JH, 2008) |
| "We developed a guinea pig model of cryptococcal meningitis to evaluate antifungal agents." | 1.34 | New guinea pig model of Cryptococcal meningitis. ( Bocanegra, R; Graybill, JR; Kirkpatrick, WR; Najvar, LK; Patterson, TF, 2007) |
| " Accordingly, we made the diagnosis of cryptococcal meningitis and immediately started multiple anti fungal drugs with dosage modification according to her impaired renal function." | 1.34 | [A case of cryptococcal meningitis with nephrotic syndrome and renal insufficiency under immunosuppressive therapy]. ( Ichikawa, D; Kimura, K; Sato, T; Shima, Y; Tsuchida, H; Yasuda, T, 2007) |
| "In 2000, cryptococcal meningitis was a common HIV related opportunistic infection in central Thailand requiring inpatient management but few patients suffering from it could afford a full course of treatment once infection had occurred." | 1.34 | Human immunodeficiency virus (HIV) related cryptococcal meningitis in rural central Thailand--treatment difficulties and prevention strategies. ( Inverarity, D; Wright, P, 2007) |
| "Two patients with HIV/AIDS (CD4 counts of 8 and 81 cells/mm(3)) presented with altered mental status, visual changes, florid cryptococcal meningitis, and elevated ICP (>500 mm CSF) without evidence of hydrocephalus on computed tomography scan." | 1.33 | The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. ( McGirt, MJ; Rigamonti, D; Williams, MA; Woodworth, GF, 2005) |
| "A case is reported of cryptococcal meningitis in a 27-y-old male suffering from X-linked hyper-IgM1 syndrome." | 1.33 | Cryptococcal meningitis in a patient with X-linked hyper-IgM1 syndrome. ( de Górgolas, M; Erice, A; Gil, A; Gutiérrez, J; Hernando, C; Rivas, P; Rodríguez, MC, 2005) |
| " Regression analysis was used to assess the correspondence between the in vitro fluconazole concentration-response curve and the murine dose-response curve observed in our previously reported murine model." | 1.33 | Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans. ( Bauer, M; Citron, D; Harrison, TS; Larsen, RA; Rathbun, M; Sanchez, A; Thomas, AM, 2005) |
| "Fluconazole was the only systemic antifungal therapy available in our centre." | 1.33 | Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. ( Maartens, G; Meintjes, GA; Morroni, C; Post, FA; Schaars, CF, 2006) |
| "Cryptococcal meningitis is an uncommon but often fatal complication of systemic lupus erythematosus (SLE)." | 1.32 | Cryptococcal meningitis in pediatric systemic lupus erythematosus. ( Chi, C; Chiu, C; Fu, L; Liou, J; Tseng, C, 2003) |
| "Albaconazole was 100-fold more potent in vitro than fluconazole on a per-weight basis and was fungicidal at potentially relevant concentrations for two isolates." | 1.32 | In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. ( Bartroli, J; Benjamin, DK; Boyce, M; Miller, JL; Perfect, JR; Schell, WA; Toffaletti, DL; Wills, EA, 2004) |
| "Amphotericin B was tested at 0." | 1.32 | Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. ( Bauer, M; Graybill, JR; Larsen, RA; Thomas, AM, 2004) |
| "Cryptococcal meningitis is the third-most-common opportunistic infection in HIV patients in Cambodia." | 1.32 | Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. ( Buisson, Y; Keo, C; Monchy, D; Sar, B; Sarthou, JL; Vann, M, 2004) |
| "75 mg/kg), administered singly or in combination with flucytosine (100 mg/kg)." | 1.31 | Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model. ( Ghannoum, MA; Hossain, MA; Long, L; Mukherjee, PK; Reyes, G, 2002) |
| " Ventricular drainage and amphotericin B intraventricularly via an implanted tube into dilated ventricle could improve the clinical condition of serious cryptococcal meningitis and decrease the dosage of systemic use of amphotericin B, therefore, reduce the side-effects of the drugs." | 1.31 | [A clinical study of 26 cases of cryptococcal meningitis]. ( Li, T; Liu, Z; Qin, S; Sheng, R; Wang, A, 2002) |
| "Fluconazole is a commonly prescribed antifungal agent with a favorable safety profile." | 1.31 | Fluconazole-induced agranulocytosis with eosinophilia. ( Shriner, K; Wong-Beringer, A, 2000) |
| "There are few reports on cryptococcal meningitis in non-HIV-infected patients in subtropical areas." | 1.31 | Cryptococcal meningitis in non-HIV-infected patients. ( Chang, SC; Chen, YC; Hsieh, WC; Luh, KT; Shih, CC, 2000) |
| "Cryptococcal meningitis was the first AIDS defining illness in 210 (91%) patients." | 1.31 | Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. ( Chintu, C; Mwaba, P; Mwansa, J; Pobee, J; Portsmouth, S; Scarborough, M; Zumla, A, 2001) |
| " Three major findings were demonstrated: (i) correlation between the MICs for the isolates and the in vivo effectiveness of fluconazole as assessed by the reduction in cryptococcal brain burden, (ii) a dose-response curve (a higher dose of fluconazole was significantly more efficacious than a lower dose [P < 0." | 1.30 | Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. ( Graybill, JR; Najvar, LK; Nguyen, MH; Yu, CY, 1997) |
| "Fluconazole is an azole antifungal agent." | 1.30 | Adverse reactions to fluconazole: illustrative case with focus on desensitization. ( Craig, TJ, 1997) |
| "Treatment with flucytosine with or without fluconazole dissolved in the sole source of drinking water was started on day 2; animals were sacrificed at 16 days, and the numbers of fungal colonies in the brain were quantified." | 1.30 | Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. ( Bauer, M; Daniel, BE; Diamond, DM; Ding, JC; Graybill, JR; Johnson, D; Larsen, RA; Leal, MA; Najvar, L; Thomas, AM; Williams, BK, 1998) |
| "neofomans from 120 Ugandan AIDS patients with cryptococcal meningitis by analyzing their electrophoretic karyotypes and antifungal susceptibility profiles." | 1.30 | Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. ( Ghannoum, M; Jessup, C; Mbidde, E; Messer, S; Pfaller, M; Tumberland, M; Zhang, J, 1998) |
| "To identify the risk factors for cryptococcal meningitis in patients with HIV disease we conducted a nested case-control study of 37 incident cases of cryptococcal meningitis and 74 controls, identified from a cohort of more than 2000 HIV-infected patients." | 1.30 | Risk factors for cryptococcal meningitis in HIV-infected patients. ( Chaisson, RE; Moore, RD; Oursler, KA, 1999) |
| "Infarctions though rare in cryptococcal meningitis should be considered in patients with chronic meningitis with vasculitis." | 1.30 | Midbrain infarction: a rare presentation of cryptococcal meningitis. ( Ayagiri, A; Bansal, R; Kalita, J; Misra, UK, 1999) |
| "Seventy-one patients with cryptococcal meningitis, 46 males and 25 females, aged 15-83 years, were included in this study." | 1.30 | The prognostic factors of cryptococcal meningitis in HIV-negative patients. ( Chang, HW; Chang, WN; Chuang, YC; Lu, CH, 1999) |
| "Four patients with cryptococcal meningitis have been treated with fluconazole in the past two years at the Department of Neurology, National Cheng Kung University Medical Center." | 1.29 | [Clinical experience with fluconazole monotherapy in cryptococcal meningitis: report of four cases]. ( La, ML; Ong, CT; Tsai, JJ, 1993) |
| "Patients with cryptococcal meningitis tend to have recurrences of infection." | 1.29 | Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. ( Casadevall, A; Freundlich, LF; Spitzer, ED; Spitzer, SG, 1993) |
| "Cryptococcal meningitis was diagnosed in a 71-year-old male diabetic patient with underlying ischaemic heart disease, asthma and bilateral axillo-femoral vascular grafts." | 1.29 | Pyrolysis typing of isolates from a recurrence of systemic cryptococcosis. ( Hosein, IK; Magee, JT; Philpot, C; Yang, J, 1994) |
| "Treatment with fluconazole resulted in poor clinical and mycological response." | 1.29 | Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. ( Bobbaers, H; Peetermans, W; Vandepitte, J; Verhaegen, J, 1993) |
| "The problem of cryptococcal meningitis is likely to become increasingly common as HIV infection becomes more widespread." | 1.29 | Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. ( Maher, D; Mwandumba, H, 1994) |
| "The above study was intended to evaluate certain pharmacokinetic properties as well as the pharmacological activity of fluconazole in patients with cryptococcal meningitis." | 1.29 | [Clinical and pharmacokinetic observations on fluconazole in the management of cryptococcal meningitis]. ( Arduino, C; Bertucci, R; Leggieri, A; Milano, R; Preziosi, C; Veglio, V, 1993) |
| " The optimal dosage of fluconazole and the impact of combination with flucytosine are not known." | 1.29 | Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. ( Elliott, BR; Kartalija, M; Kaye, K; Liu, Q; Sande, MA; Täuber, MG; Tureen, JH, 1996) |
| "Fluconazole is an alternative therapy, but its efficacy has not been documented in the patient population not infected with HIV." | 1.29 | Fluconazole and amphotericin B for cryptococcal meningitis. ( Clark, AB; Gelfand, MS; Lobo, BL, 1996) |
| "Eighteen consecutive AIDS patients with a first episode of cryptococcal meningitis were enrolled in the study to evaluate the efficacy and tolerability of amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS." | 1.29 | Amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS. ( Jaruratanasirikul, S, 1996) |
| "The use of preventive treatment for fungal infections is cautioned due to the possibility of resistance to treatment." | 1.29 | Fungal infection overview. ( , 1995) |
| "Symptoms of cryptococcal meningitis appear gradually and generally include headache, fever, or malaise." | 1.29 | Cryptococcosis. ( Powderly, WG, 1996) |
| "Treatment with fluconazole seems to be an effective alternative in treatment of CNM." | 1.28 | [Fluconazole treatment of cryptococcal meningitis associated with HIV infection. Presentation of 4 cases]. ( Bernacer, B; Carrasco, R; Navarro, V; Nieto, A; Rodríguez, M; Roig, P; Salavert, M, 1992) |
| "Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) is particularly common in tropical Africa." | 1.28 | Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) in African patients: treatment with fluconazole. ( Aubry, P; Bogaerts, J; Dupont, B; Durbec, JP; Kadio, A; Laroche, R; Latif, A; M'Pele, P; Taelman, H; Touze, JE, 1992) |
| "Eight patients with AIDS were treated orally with 800 mg of fluconazole daily for cryptococcal meningitis for a mean duration of 4." | 1.28 | Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. ( Berry, AJ; Graybill, JR; Rinaldi, MG, 1992) |
| "Fluconazole has shown effectiveness in maintenance therapy, being not be possible to evaluate it as an acute phase therapy because the low number of cases in which it was studied." | 1.28 | [Cryptococcosis in AIDS patients: a study of 19 cases]. ( Adrados de Llano, M; García Aguado, C; Gazapo Carretero, E; González Lahoz, JM; Martínez Blanco, ML; Verdejo Ortes, J, 1992) |
| " Because amphotericin B nephrotoxicity was suspected, further intravenous administration was stopped after a cumulative dosage of 2 g." | 1.28 | [Cryptococcal meningitis in AIDS: successful long-term prophylaxis with fluconazole]. ( Glück, T; Weber, P; Wiedmann, KH, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 97 (27.17) | 18.2507 |
| 2000's | 100 (28.01) | 29.6817 |
| 2010's | 110 (30.81) | 24.3611 |
| 2020's | 50 (14.01) | 2.80 |
| Authors | Studies |
|---|---|
| Kirkpatrick, WR | 3 |
| Najvar, LK | 5 |
| Bocanegra, R | 2 |
| Patterson, TF | 3 |
| Graybill, JR | 12 |
| Tu, J | 2 |
| Li, Z | 2 |
| Jiang, Y | 4 |
| Ji, C | 2 |
| Han, G | 1 |
| Wang, Y | 3 |
| Liu, N | 2 |
| Sheng, C | 2 |
| Li, W | 1 |
| Yun, Z | 1 |
| Yang, W | 1 |
| Li, J | 1 |
| Ngan, NTT | 3 |
| Thanh Hoang Le, N | 1 |
| Vi Vi, NN | 1 |
| Van, NTT | 1 |
| Mai, NTH | 1 |
| Van Anh, D | 2 |
| Trieu, PH | 1 |
| Lan, NPH | 2 |
| Phu, NH | 1 |
| Chau, NVV | 2 |
| Lalloo, DG | 9 |
| Hope, W | 6 |
| Beardsley, J | 1 |
| White, NJ | 3 |
| Geskus, R | 1 |
| Thwaites, GE | 2 |
| Krysan, D | 2 |
| Tai, LTH | 1 |
| Kestelyn, E | 1 |
| Binh, TQ | 1 |
| Hung, LQ | 1 |
| Tung, NLN | 1 |
| Day, JN | 4 |
| Liu, J | 6 |
| Li, M | 5 |
| Liang, JY | 1 |
| Xu, XF | 1 |
| Zeng, WG | 1 |
| Wang, YJ | 1 |
| Peng, FH | 2 |
| Ohnishi, YO | 1 |
| Pantoja, ASL | 1 |
| Abraão, LSO | 1 |
| Alves, NG | 1 |
| Ohnishi, MDO | 1 |
| Libonati, RMF | 1 |
| Ventura, AMRDS | 1 |
| Palácios, VRDCM | 1 |
| Rajasingham, R | 9 |
| Nalintya, E | 5 |
| Israelski, DM | 1 |
| Meya, DB | 12 |
| Larson, BA | 1 |
| Boulware, DR | 20 |
| Nelles, R | 1 |
| Britton, S | 1 |
| John, GT | 1 |
| Denaro, C | 1 |
| Jarvis, JN | 17 |
| Lawrence, DS | 6 |
| Kagimu, E | 1 |
| Kasibante, J | 1 |
| Mpoza, E | 2 |
| Rutakingirwa, MK | 2 |
| Ssebambulidde, K | 3 |
| Tugume, L | 4 |
| Rhein, J | 5 |
| Mwandumba, HC | 3 |
| Moyo, M | 1 |
| Mzinganjira, H | 1 |
| Kanyama, C | 7 |
| Hosseinipour, MC | 8 |
| Chawinga, C | 4 |
| Meintjes, G | 12 |
| Schutz, C | 4 |
| Comins, K | 1 |
| Singh, A | 1 |
| Muzoora, C | 7 |
| Jjunju, S | 1 |
| Nuwagira, E | 3 |
| Mosepele, M | 3 |
| Leeme, T | 2 |
| Siamisang, K | 1 |
| Ndhlovu, CE | 4 |
| Hlupeni, A | 2 |
| Mutata, C | 1 |
| van Widenfelt, E | 1 |
| Chen, T | 4 |
| Wang, D | 3 |
| Boyer-Chammard, T | 4 |
| Loyse, A | 11 |
| Molloy, SF | 10 |
| Youssouf, N | 2 |
| Lortholary, O | 15 |
| Jaffar, S | 11 |
| Harrison, TS | 33 |
| Temfack, E | 8 |
| Mashau, RC | 1 |
| Meiring, ST | 1 |
| Quan, VC | 1 |
| Nel, J | 1 |
| Greene, GS | 1 |
| Garcia, A | 1 |
| Menezes, C | 1 |
| Reddy, DL | 1 |
| Venter, M | 1 |
| Stacey, S | 1 |
| Madua, M | 1 |
| Boretti, L | 1 |
| Shroufi, A | 2 |
| Trivino-Duran, L | 1 |
| Black, J | 1 |
| Govender, NP | 2 |
| Su, X | 1 |
| Yang, L | 1 |
| Wang, A | 2 |
| Xu, X | 4 |
| Peng, F | 3 |
| Falci, DR | 1 |
| Pasqualotto, AC | 2 |
| Zhao, T | 1 |
| Wu, Y | 1 |
| Zhang, W | 1 |
| Zeng, Q | 1 |
| Lu, Y | 1 |
| Yang, T | 1 |
| Zhou, G | 1 |
| Yu, J | 1 |
| Lan, K | 1 |
| Harypursat, V | 1 |
| Chen, Y | 2 |
| Burry, J | 2 |
| Casas, CP | 1 |
| Ford, N | 6 |
| Zhao, HZ | 2 |
| Cheng, JH | 2 |
| Zhou, LH | 2 |
| Luo, Y | 1 |
| Zhu, RS | 1 |
| Jiang, YK | 2 |
| Wang, X | 3 |
| Zhu, LP | 2 |
| Flower, B | 1 |
| Shapiro, AE | 2 |
| Tenforde, MW | 3 |
| Chiller, TM | 1 |
| Ssali, A | 1 |
| Moshashane, N | 1 |
| Nabaggala, G | 1 |
| Maphane, L | 1 |
| Seeley, J | 1 |
| Samukawa, S | 3 |
| Yoshimi, R | 3 |
| Kojitani, N | 3 |
| Uzawa, Y | 3 |
| Takase-Minegishi, K | 3 |
| Kirino, Y | 3 |
| Soejima, Y | 3 |
| Kato, H | 3 |
| Nakajima, H | 3 |
| Lalloo, UG | 1 |
| Komarow, L | 1 |
| Aberg, JA | 1 |
| Clifford, DB | 1 |
| Hogg, E | 1 |
| McKhann, A | 1 |
| Bukuru, A | 1 |
| Lagat, D | 1 |
| Pillay, S | 1 |
| Mave, V | 1 |
| Supparatpinyo, K | 6 |
| Samaneka, W | 1 |
| Langat, D | 1 |
| Ticona, E | 2 |
| Badal-Faesen, S | 1 |
| Larsen, RA | 17 |
| Loua, OO | 1 |
| Alle Akakpo, AE | 1 |
| Ouedraogo, D | 1 |
| Cissoko, Y | 1 |
| Soumaré, M | 2 |
| Konaté, I | 1 |
| Dao, S | 1 |
| Huang, Q | 1 |
| Hong, Z | 1 |
| Hong, Q | 1 |
| Giamberardino, CD | 1 |
| Tenor, JL | 1 |
| Toffaletti, DL | 2 |
| Palmucci, JR | 1 |
| Schell, W | 1 |
| Boua, J-VK | 1 |
| Marius, C | 1 |
| Stott, KE | 2 |
| Steele, SL | 1 |
| Cilla, D | 1 |
| Perfect, JR | 5 |
| Alanazi, AH | 1 |
| Chastain, DB | 1 |
| Rudraraju, M | 1 |
| Parvathagiri, V | 1 |
| Shan, S | 1 |
| Lin, X | 1 |
| Henao-Martínez, AF | 1 |
| Franco-Paredes, C | 1 |
| Narayanan, SP | 1 |
| Somanath, PR | 1 |
| Alhadab, AA | 2 |
| Musubire, A | 1 |
| Williams, DA | 2 |
| Abassi, M | 3 |
| Nicol, MR | 1 |
| Brundage, RC | 1 |
| Lawrence, D | 1 |
| Delliere, S | 1 |
| Lanternier, F | 2 |
| Alanio, A | 3 |
| Pastick, KA | 2 |
| Stephens, N | 1 |
| Evans, EE | 2 |
| Ndyetukira, JF | 1 |
| Skipper, C | 1 |
| Bandadi, FZ | 1 |
| Raiss, C | 1 |
| Moustachi, A | 1 |
| Lyagoubi, M | 2 |
| Aoufi, S | 1 |
| Kassi, FK | 2 |
| Drakulovski, P | 1 |
| Bellet, V | 1 |
| Roger, F | 1 |
| Chabrol, A | 1 |
| Krasteva, D | 1 |
| Doumbia, A | 2 |
| Landman, R | 1 |
| Kakou, A | 1 |
| Reynes, J | 1 |
| Delaporte, E | 2 |
| Menan, HEI | 1 |
| Bertout, S | 2 |
| Pullen, MF | 1 |
| Hullsiek, KH | 3 |
| Musubire, AK | 2 |
| Kiggundu, R | 1 |
| Akampurira, A | 2 |
| Nabeta, HW | 1 |
| Skipper, CP | 2 |
| Morawski, BM | 1 |
| Bangdiwala, AS | 2 |
| Gertz, AM | 1 |
| Wills, NK | 1 |
| Guthrie, BL | 1 |
| Farquhar, C | 1 |
| Otto, SBJ | 1 |
| George, PE | 1 |
| Mercedes, R | 1 |
| Nabukeera-Barungi, N | 1 |
| Lakoh, S | 1 |
| Rickman, H | 1 |
| Sesay, M | 1 |
| Kenneh, S | 1 |
| Burke, R | 1 |
| Baldeh, M | 1 |
| Jiba, DF | 1 |
| Tejan, YS | 1 |
| Boyle, S | 1 |
| Koroma, C | 1 |
| Deen, GF | 1 |
| Beynon, F | 1 |
| Vanherp, L | 2 |
| Poelmans, J | 2 |
| Hillen, A | 2 |
| Janbon, G | 1 |
| Brock, M | 1 |
| Lagrou, K | 2 |
| Vande Velde, G | 2 |
| Himmelreich, U | 2 |
| Kalinoski, T | 1 |
| Malenfant, J | 1 |
| Yim, C | 1 |
| Jeng, A | 1 |
| Wambaugh, MA | 1 |
| Denham, ST | 1 |
| Ayala, M | 1 |
| Brammer, B | 1 |
| Stonhill, MA | 1 |
| Brown, JC | 1 |
| Kirumira, P | 1 |
| Naluyima, R | 1 |
| Turya, F | 1 |
| Namanda, S | 1 |
| Nikweri, Y | 2 |
| Murphy, LS | 1 |
| Lacy, AJ | 1 |
| Smith, AT | 1 |
| Shah, KS | 1 |
| Hu, D | 1 |
| Zhang, Q | 2 |
| Jiang, W | 1 |
| Arastehfar, A | 1 |
| Ilkit, M | 1 |
| Fang, W | 1 |
| Li, H | 1 |
| Chen, X | 1 |
| Zhang, L | 1 |
| Li, X | 2 |
| Pan, W | 1 |
| Liao, W | 3 |
| O'Connor, L | 1 |
| Chau, TTH | 1 |
| Huong, LNP | 1 |
| Wolbers, M | 1 |
| Mejia-Chew, C | 1 |
| Sung, A | 1 |
| Larson, L | 1 |
| Powderly, WG | 11 |
| Spec, A | 1 |
| Weerasekera, A | 1 |
| Croitor-Sava, AR | 1 |
| Sorrell, TC | 2 |
| Deng, X | 1 |
| Gan, Q | 1 |
| Kitonsa, J | 2 |
| Nsubuga, R | 1 |
| Mayanja, Y | 2 |
| Kiwanuka, J | 2 |
| Onyango, M | 1 |
| Anywaine, Z | 2 |
| Ggayi, AB | 2 |
| Kibengo, FM | 1 |
| Kaleebu, P | 2 |
| Day, J | 3 |
| Vidal, JE | 2 |
| de Albuquerque Moraes, C | 1 |
| de Siqueira, REB | 1 |
| Miranda, NFB | 1 |
| Marcusso, R | 1 |
| de Oliveira, ACP | 1 |
| Anjum, S | 1 |
| Dean, O | 1 |
| Kosa, P | 1 |
| Magone, MT | 1 |
| King, KA | 1 |
| Fitzgibbon, E | 1 |
| Kim, HJ | 1 |
| Zalewski, C | 1 |
| Murphy, E | 1 |
| Billioux, BJ | 1 |
| Chisholm, J | 1 |
| Brewer, CC | 1 |
| Krieger, C | 1 |
| Elsegeiny, W | 1 |
| Scott, TL | 1 |
| Wang, J | 1 |
| Hunsberger, S | 1 |
| Bennett, JE | 1 |
| Nath, A | 1 |
| Marr, KA | 1 |
| Bielekova, B | 1 |
| Wendler, D | 1 |
| Hammoud, DA | 1 |
| Williamson, P | 1 |
| Warrell, CE | 1 |
| Macrae, C | 1 |
| McLean, ARD | 1 |
| Wilkins, E | 1 |
| Ashley, EA | 1 |
| Smithuis, F | 1 |
| Tun, NN | 1 |
| Drain, PK | 1 |
| Galagan, SR | 1 |
| Govere, S | 1 |
| Krows, M | 1 |
| Thulare, H | 1 |
| Wallis, CL | 1 |
| Gosnell, BI | 1 |
| Moosa, MY | 1 |
| Celum, C | 1 |
| Bassett, IV | 1 |
| Bremer, M | 1 |
| Kadernani, YE | 1 |
| Wasserman, S | 1 |
| Wilkinson, RJ | 1 |
| Davis, AG | 1 |
| Ding, JZ | 1 |
| Torres, C | 1 |
| Concha-Velasco, F | 1 |
| González-Lagos, E | 1 |
| Seas, C | 1 |
| Bustamante, B | 2 |
| Frola, C | 1 |
| Guelfand, L | 2 |
| Blugerman, G | 1 |
| Szyld, E | 1 |
| Kaufman, S | 1 |
| Cahn, P | 2 |
| Sued, O | 1 |
| Pérez, H | 1 |
| de Carvalho Santana, R | 1 |
| Schiave, LA | 1 |
| Dos Santos Quaglio, AS | 1 |
| de Gaitani, CM | 1 |
| Martinez, R | 1 |
| Lahiri Mukhopadhyay, S | 1 |
| Bahubali, VH | 1 |
| Manjunath, N | 1 |
| Swaminathan, A | 1 |
| Maji, S | 1 |
| Palaniappan, M | 1 |
| Parthasarathy, S | 1 |
| Chandrashekar, N | 2 |
| Ming, DK | 1 |
| Johnson, KL | 1 |
| James, MD | 1 |
| Carrera-Justiz, S | 1 |
| Hatlen, TJ | 2 |
| Murphy, RA | 2 |
| Persichino, JG | 1 |
| Wirth, F | 1 |
| de Azevedo, MI | 1 |
| Pilla, C | 1 |
| Aquino, VR | 2 |
| Neto, GW | 1 |
| Goldani, LZ | 2 |
| Beyene, T | 1 |
| Zewde, AG | 1 |
| Balcha, A | 1 |
| Hirpo, B | 1 |
| Yitbarik, T | 1 |
| Gebissa, T | 1 |
| Pasquier, E | 1 |
| Kunda, J | 1 |
| De Beaudrap, P | 1 |
| Moosa, MS | 1 |
| Bongomin, F | 1 |
| Oladele, RO | 1 |
| Gago, S | 2 |
| Moore, CB | 1 |
| Richardson, MD | 1 |
| Abbas, H | 1 |
| CiFuentes Kottkamp, A | 1 |
| Abbas, N | 1 |
| Cindrich, R | 1 |
| Singh, M | 1 |
| Lofgren, S | 2 |
| Huppler Hullsiek, K | 1 |
| Heyderman, RS | 7 |
| Kouanfack, C | 4 |
| Chanda, D | 4 |
| Mfinanga, S | 4 |
| Lakhi, S | 4 |
| Lesikari, S | 2 |
| Chan, AK | 3 |
| Stone, N | 2 |
| Kalata, N | 3 |
| Karunaharan, N | 2 |
| Gaskell, K | 2 |
| Peirse, M | 2 |
| Ellis, J | 1 |
| Lontsi, S | 1 |
| Ndong, JG | 1 |
| Bright, P | 2 |
| Lupiya, D | 2 |
| Bradley, J | 2 |
| Adams, J | 2 |
| van der Horst, C | 4 |
| van Oosterhout, JJ | 3 |
| Sini, V | 2 |
| Mapoure, YN | 2 |
| Mwaba, P | 4 |
| Bicanic, T | 9 |
| Xu, L | 1 |
| Liao, J | 1 |
| Kuang, W | 1 |
| Zhu, C | 1 |
| Yi, H | 1 |
| Johnson, WJ | 1 |
| Blice, JP | 1 |
| Lee, KK | 1 |
| Uppar, A | 1 |
| Raj, ARP | 1 |
| Konar, S | 1 |
| Kandregula, S | 1 |
| Shukla, D | 1 |
| Somanna, S | 1 |
| Devi, BI | 1 |
| C, Y | 1 |
| Mosojane, KI | 1 |
| Sowash, M | 1 |
| Williams, VL | 1 |
| Kovarik, CL | 1 |
| Chimowa, T | 1 |
| King, I | 1 |
| Iroh Tam, PY | 1 |
| Gonzalez-Martinez, C | 1 |
| Wiederhold, NP | 2 |
| Garvey, EP | 1 |
| Brand, SR | 1 |
| Ottinger, EA | 1 |
| Alimardanov, A | 1 |
| Cradock, J | 1 |
| Behnke, M | 1 |
| Hoekstra, WJ | 1 |
| Schotzinger, RJ | 1 |
| Jaramillo, R | 1 |
| Olivo, M | 1 |
| Bigna, JJ | 1 |
| Luma, HN | 1 |
| Spijker, R | 1 |
| Dromer, F | 5 |
| Harrison, T | 4 |
| Cohen, JF | 1 |
| Eshun-Wilson, I | 3 |
| Okwen, MP | 1 |
| Richardson, M | 1 |
| Rouse, B | 1 |
| Li, T | 2 |
| Lofgren, SM | 1 |
| Mputu, M | 1 |
| Phulusa, J | 3 |
| Segula, D | 1 |
| Ming, D | 1 |
| Ellis, JP | 1 |
| Joekes, EC | 1 |
| Kampondeni, S | 1 |
| Benjamin, LA | 1 |
| Cohn, J | 1 |
| Chiller, T | 1 |
| Ribeiro, I | 1 |
| Koulla-Shiro, S | 1 |
| Mghamba, J | 1 |
| Ramadhani, A | 1 |
| Nyirenda, R | 1 |
| Aliyu, SH | 1 |
| Wilson, D | 1 |
| Le, T | 1 |
| Oladele, R | 1 |
| Mapoure, Y | 1 |
| Shimwela, M | 1 |
| Ngoma, J | 1 |
| Gondwe-Chunda, L | 1 |
| Perfect, C | 1 |
| Andrieux-Meyer, I | 1 |
| Chan, A | 1 |
| Hosseinipour, M | 1 |
| Klausner, JD | 1 |
| Heyderman, R | 1 |
| Lalloo, D | 1 |
| Rodrigues, M | 1 |
| Denning, D | 1 |
| Migone, C | 2 |
| Doherty, M | 1 |
| Stack, M | 1 |
| van Oosterhout, J | 1 |
| Govender, N | 2 |
| Faini, D | 1 |
| Kalinjuma, AV | 1 |
| Katende, A | 1 |
| Mbwaji, G | 1 |
| Mnzava, D | 1 |
| Nyuri, A | 1 |
| Glass, TR | 1 |
| Furrer, H | 1 |
| Hatz, C | 1 |
| Letang, E | 2 |
| Alufandika, M | 1 |
| Niessen, L | 1 |
| Garner, P | 1 |
| Wang, RY | 1 |
| Huang, LP | 1 |
| Owuor, OH | 1 |
| Chege, P | 1 |
| Stone, NR | 1 |
| Rhodes, J | 1 |
| Fisher, MC | 1 |
| Kivuyo, S | 2 |
| Rugemalila, J | 1 |
| Segal, ES | 1 |
| Needleman, L | 1 |
| Kwon-Chung, J | 1 |
| Berman, J | 1 |
| Aling, E | 1 |
| Namutundu, J | 1 |
| Kibengo, F | 1 |
| Kiwanuka, N | 1 |
| Shiri, T | 1 |
| Mwenge, L | 1 |
| Niessen, LW | 1 |
| Liu, Y | 1 |
| Chong, Y | 1 |
| Jie, Y | 1 |
| Zheng, X | 1 |
| Yan, Y | 1 |
| Khattab, A | 1 |
| Patruni, S | 1 |
| Sealey, ML | 1 |
| Hai, TP | 1 |
| Van, AD | 1 |
| Nhat, LTH | 1 |
| Vinh Chau, NV | 1 |
| Wake, RM | 1 |
| Omar, T | 1 |
| Nel, C | 1 |
| Mazanderani, AH | 1 |
| Karat, AS | 1 |
| Ismail, NA | 1 |
| Tiemessen, CT | 1 |
| Borges, MASB | 1 |
| de Araújo Filho, JA | 1 |
| Oliveira, BJS | 1 |
| Moreira, IS | 1 |
| de Paula, VV | 1 |
| de Bastos, AL | 1 |
| Soares, RBA | 1 |
| Turchi, MD | 1 |
| Trpković, A | 1 |
| Pekmezović, M | 1 |
| Barać, A | 1 |
| Crnčević Radović, L | 1 |
| Arsić Arsenijević, V | 1 |
| Sudan, A | 1 |
| Livermore, J | 1 |
| Howard, SJ | 1 |
| Al-Nakeeb, Z | 1 |
| Sharp, A | 1 |
| Goodwin, J | 1 |
| Gregson, L | 1 |
| Warn, PA | 1 |
| Felton, TW | 1 |
| Hope, WW | 1 |
| Mete, B | 1 |
| Saltoglu, N | 1 |
| Vanli, E | 1 |
| Ozkara, C | 1 |
| Arslan, F | 1 |
| Mert, A | 1 |
| Ozaras, R | 1 |
| Tabak, F | 1 |
| Ozturk, R | 1 |
| Rothe, C | 2 |
| Sloan, DJ | 3 |
| Goodson, P | 2 |
| Chikafa, J | 1 |
| Mukaka, M | 1 |
| Denis, B | 1 |
| Allain, T | 1 |
| Feasey, NA | 2 |
| Iyer, SP | 1 |
| Movva, K | 1 |
| Wiebel, M | 1 |
| Chandrasekar, P | 1 |
| Alangaden, G | 1 |
| Carron, M | 1 |
| Tranchida, P | 1 |
| Revankar, SG | 1 |
| Zhong, YH | 1 |
| Tan, F | 1 |
| Yuan, Y | 1 |
| Zhong, XF | 1 |
| Yao, ZW | 1 |
| Lu, X | 1 |
| Shen, C | 1 |
| Lin, DF | 1 |
| Meda, J | 1 |
| Kalluvya, S | 2 |
| Downs, JA | 1 |
| Chofle, AA | 2 |
| Seni, J | 1 |
| Kidenya, B | 1 |
| Fitzgerald, DW | 1 |
| Peck, RN | 1 |
| Chaaban, S | 1 |
| Wheat, LJ | 1 |
| Assi, M | 1 |
| Sakamoto, N | 1 |
| Maeda, T | 1 |
| Mikita, K | 1 |
| Kato, Y | 1 |
| Yanagisawa, N | 1 |
| Suganuma, A | 1 |
| Imamura, A | 1 |
| Nakamura-Uchiyama, F | 1 |
| Miyahira, Y | 1 |
| Kawana, A | 1 |
| Ohnishi, K | 1 |
| Ajisawa, A | 1 |
| Newsome, J | 1 |
| Nguyen, D | 1 |
| Gaskell, KM | 1 |
| Gnanadurai, R | 1 |
| Jassi, C | 1 |
| Allain, TJ | 1 |
| Odashima, K | 1 |
| Takayanagi, N | 1 |
| Ishiguro, T | 1 |
| Shimizu, Y | 1 |
| Sugita, Y | 1 |
| Kammalac Ngouana, T | 1 |
| Dongtsa, J | 1 |
| Tonfack, C | 1 |
| Fomena, S | 1 |
| Mallié, M | 1 |
| Boyom, FF | 1 |
| Katchanov, J | 2 |
| Blechschmidt, C | 1 |
| Nielsen, K | 2 |
| Branding, G | 2 |
| Arastéh, K | 2 |
| Tintelnot, K | 1 |
| Stocker, H | 2 |
| Sangarlangkarn, A | 1 |
| Rughwani, N | 1 |
| Jefferys, L | 1 |
| Siebert, E | 1 |
| van Spil, WE | 1 |
| Nooijen, S | 1 |
| de Jong, PY | 1 |
| Aliredjo, RP | 1 |
| de Sévaux, RG | 1 |
| Verhave, JC | 1 |
| Molefi, M | 1 |
| Changalucha, JM | 1 |
| Cainelli, F | 1 |
| Lekwape, N | 1 |
| Goldberg, DW | 1 |
| Haverkamp, M | 1 |
| Bisson, GP | 1 |
| Fenner, L | 1 |
| Burton, R | 1 |
| Makadzange, T | 1 |
| Gbané-Koné, M | 1 |
| Ouali, B | 1 |
| Mègne, E | 1 |
| Diomandé, M | 1 |
| Coulibaly, AK | 1 |
| Eti, E | 1 |
| Kouakou, NM | 1 |
| Yao, Y | 1 |
| Zhang, JT | 1 |
| Yan, B | 1 |
| Gao, T | 1 |
| Xing, XW | 1 |
| Tian, CL | 1 |
| Huang, XS | 1 |
| Yu, SY | 1 |
| Adeyemi, BO | 1 |
| Ross, A | 1 |
| Smith, KD | 1 |
| Achan, B | 1 |
| McDonald, TR | 1 |
| Okagaki, LH | 1 |
| Rhein, JR | 1 |
| Animalu, C | 1 |
| Mazumder, S | 1 |
| Cleveland, KO | 1 |
| Gelfand, MS | 2 |
| Nath, R | 1 |
| Laskar, B | 1 |
| Ahmed, J | 1 |
| Das, S | 1 |
| Timung, L | 1 |
| Saikia, L | 1 |
| Potapenko, VG | 1 |
| Konovalenko, IB | 1 |
| Oksema, ЕV | 1 |
| Filippova, LN | 1 |
| Dulaeva, EN | 1 |
| Derevyannykh, NА | 1 |
| Krasnoruzhsky, АI | 1 |
| Klimovich, AV | 1 |
| Klimko, NN | 1 |
| Medvedeva, NV | 1 |
| Córdoba, S | 1 |
| Isla, MG | 1 |
| Szusz, W | 1 |
| Vivot, W | 1 |
| Altamirano, R | 1 |
| Davel, G | 2 |
| Rachadi, H | 1 |
| Senouci, K | 1 |
| Benzekri, A | 1 |
| Mansouri, S | 1 |
| Ramli, I | 1 |
| Ismaili, N | 1 |
| Hassam, B | 1 |
| Benzekri, L | 1 |
| Merry, M | 1 |
| Serrano, C | 1 |
| Alastruey-Izquierdo, A | 1 |
| Cuesta, I | 1 |
| Martín-Mazuelos, E | 1 |
| Aller, AI | 1 |
| Gómez-López, A | 1 |
| Mellado, E | 2 |
| Grossman, NT | 1 |
| Casadevall, A | 3 |
| Kouakou, GA | 1 |
| Ello, NF | 1 |
| Kassi, NA | 1 |
| Keita, M | 1 |
| Mossou, C | 1 |
| Tanon, A | 1 |
| Ehui, E | 1 |
| Eholié, SP | 1 |
| Cartner, M | 1 |
| Holley, A | 1 |
| Allworth, A | 1 |
| Swe Han, KS | 1 |
| Bekker, A | 1 |
| Greeff, S | 1 |
| Perkins, DR | 1 |
| Dammert, P | 1 |
| Llanos-Cuentas, A | 1 |
| Huaroto, L | 1 |
| Chávez, VM | 1 |
| Campos, PE | 1 |
| Sloan, D | 1 |
| Dlamini, S | 1 |
| Paul, N | 1 |
| Dedicoat, M | 2 |
| Tsai, HE | 1 |
| Chou, NK | 1 |
| Chi, NH | 1 |
| Chen, YS | 1 |
| Wang, JL | 1 |
| Wang, SS | 1 |
| Minta, DK | 1 |
| Dembélé, M | 1 |
| Diarra, AS | 1 |
| Sidibé, AT | 1 |
| Konaté, A | 1 |
| Diarra, M | 1 |
| Coulibaly, I | 1 |
| Maïga, II | 1 |
| Traoré, AK | 1 |
| Maïga, MY | 1 |
| Doumbo, OK | 1 |
| Traoré, HA | 1 |
| Pichard, E | 1 |
| Chabasse, D | 1 |
| Ndiaye, M | 2 |
| Seydi, M | 1 |
| Sène-Diouf, F | 1 |
| Ngom, NF | 1 |
| Sène, MS | 2 |
| Sow, AD | 2 |
| Diop, AG | 2 |
| Sow, PS | 1 |
| Ndiaye, MM | 2 |
| Ndiaye, IP | 1 |
| Longley, N | 3 |
| Taseera, K | 2 |
| Mwesigye, J | 2 |
| Rwebembera, J | 1 |
| Chakera, A | 1 |
| Wall, E | 1 |
| Andia, I | 1 |
| Pujol, I | 1 |
| Pastor, FJ | 1 |
| dos Santos Lazéra, M | 1 |
| Guarro, J | 1 |
| Soares, BM | 1 |
| Santos, DA | 1 |
| Kohler, LM | 1 |
| da Costa César, G | 1 |
| de Carvalho, IR | 1 |
| dos Anjos Martins, M | 1 |
| Cisalpino, PS | 1 |
| Seilmaier, M | 1 |
| Hecht, A | 1 |
| Guggemos, W | 1 |
| Rüdisser, K | 1 |
| Makombe, SD | 1 |
| Nkhata, A | 1 |
| Schouten, EJ | 1 |
| Kamoto, K | 1 |
| Harries, AD | 1 |
| Seddon, J | 1 |
| Mangeya, N | 1 |
| Miller, RF | 2 |
| Corbett, EL | 1 |
| Ferrand, RA | 1 |
| Kaouech, E | 1 |
| Kallel, K | 2 |
| Belhadj, S | 2 |
| Anane, S | 1 |
| Ben Châabane, T | 1 |
| Ben Fadhl, K | 1 |
| Khedher, A | 1 |
| Meddeb, B | 1 |
| Ben Lakhal, S | 1 |
| Chaker, E | 2 |
| Pappas, PG | 5 |
| Chetchotisakd, P | 8 |
| Manosuthi, W | 7 |
| Morris, MI | 2 |
| Anekthananon, T | 5 |
| Sungkanuparph, S | 6 |
| Nolen, TL | 6 |
| Zimmer, LO | 3 |
| Kendrick, AS | 3 |
| Johnson, P | 1 |
| Sobel, JD | 3 |
| Filler, SG | 5 |
| Mehta, V | 1 |
| De, A | 1 |
| Balachandran, C | 1 |
| Monga, P | 1 |
| Dedicoat, MJ | 1 |
| Brouwer, AE | 3 |
| Rebe, K | 3 |
| Jarvis, J | 1 |
| Bekker, LG | 3 |
| Wood, R | 3 |
| Limmathurotsakul, D | 1 |
| Chierakul, W | 2 |
| Stepniewska, K | 1 |
| Guevara-Campos, J | 1 |
| González-Guevara, L | 1 |
| Urbéz-Cano, J | 1 |
| Fermín, S | 1 |
| Kopetskie, H | 1 |
| Johnson, PC | 2 |
| Blanch, JJ | 1 |
| Rodríguez, M | 2 |
| Escribano, E | 1 |
| Atienzar, M | 1 |
| Pramanpol, S | 1 |
| Wallace, D | 2 |
| Walker, ME | 1 |
| Pappas, P | 1 |
| Jiang, PF | 1 |
| Yu, HM | 1 |
| Zhou, BL | 1 |
| Gao, F | 1 |
| Shen, SX | 1 |
| Xia, ZZ | 1 |
| Shui, QX | 1 |
| Tilak, R | 1 |
| Prakash, P | 1 |
| Nigam, C | 1 |
| Tilak, V | 1 |
| Gambhir, IS | 1 |
| Gulati, AK | 1 |
| Andes, D | 1 |
| Nussbaum, JC | 2 |
| Jackson, A | 2 |
| Namarika, D | 2 |
| Kenala, J | 1 |
| Kanyemba, C | 2 |
| Kamwendo, D | 1 |
| van der Horst, CM | 2 |
| Wang, H | 1 |
| Xu, K | 1 |
| Liu, L | 1 |
| Tan, JP | 1 |
| Li, Y | 1 |
| Fan, W | 1 |
| Wei, Z | 1 |
| Sheng, J | 1 |
| Yang, YY | 1 |
| Li, L | 1 |
| Lightowler, JV | 1 |
| Cooke, GS | 1 |
| Mutevedzi, P | 1 |
| Lessells, RJ | 2 |
| Newell, ML | 2 |
| Makadzange, AT | 1 |
| Takarinda, K | 1 |
| Reid, M | 1 |
| Kurangwa, M | 1 |
| Gona, P | 1 |
| Hakim, JG | 1 |
| Williams, Z | 1 |
| Morera, N | 1 |
| Juan-Sallés, C | 1 |
| Torres, JM | 1 |
| Andreu, M | 1 |
| Sánchez, M | 1 |
| Zamora, MÁ | 1 |
| Colom, MF | 1 |
| Park, BJ | 1 |
| Shetty, S | 1 |
| Ahlquist, A | 1 |
| Greenbaum, A | 1 |
| Miller, JL | 2 |
| Motsi, A | 1 |
| McCarthy, K | 1 |
| Diagne, NR | 1 |
| Seck, LB | 1 |
| Sow, HD | 1 |
| Yuanjie, Z | 1 |
| Jianghan, C | 1 |
| Nan, X | 1 |
| Xiaojun, W | 1 |
| Hai, W | 1 |
| Wanqing, L | 1 |
| Julin, G | 1 |
| Mutevedzi, PC | 1 |
| Heller, T | 1 |
| Muzoora, CK | 1 |
| Kabanda, T | 1 |
| Ortu, G | 1 |
| Ssentamu, J | 1 |
| Hearn, P | 1 |
| Kiertiburanakul, S | 1 |
| Ratanasuwan, W | 1 |
| Kopetskie, HA | 1 |
| Shoji, H | 1 |
| Takuma, T | 1 |
| Ohbayashi, H | 1 |
| Yoshida, K | 1 |
| Yamamoto, T | 1 |
| Niki, Y | 1 |
| Ondounda, M | 1 |
| Mounguengui, D | 1 |
| Mandji, LJ | 1 |
| Magne, C | 1 |
| Nziengui, MM | 1 |
| Kombila, U | 1 |
| Nzenze, JR | 1 |
| Sachdeva, RK | 1 |
| Randev, S | 1 |
| Sharma, A | 1 |
| Wanchu, A | 1 |
| Chakrabarti, A | 1 |
| Singh, S | 1 |
| Varma, S | 1 |
| Celis-Aguilar, E | 1 |
| Macias-Valle, L | 1 |
| Coutinho-De Toledo, H | 1 |
| Milani, B | 1 |
| Jackson, AT | 1 |
| Chikasema, M | 1 |
| Rolfes, MA | 1 |
| Birkenkamp, KE | 1 |
| Meya, BD | 1 |
| Mayanja-Kizza, H | 2 |
| Lukande, R | 1 |
| Wiesner, LD | 1 |
| Bohjanen, P | 1 |
| R Boulware, RD | 1 |
| Lee, CH | 1 |
| Chang, TY | 1 |
| Liu, JW | 1 |
| Chen, FJ | 1 |
| Chien, CC | 1 |
| Tang, YF | 1 |
| Lu, CH | 2 |
| Mlinarić Missoni, E | 1 |
| Baršić, B | 1 |
| Meyer, AC | 1 |
| Kendi, CK | 1 |
| Penner, JA | 1 |
| Odhiambo, N | 1 |
| Otieno, B | 1 |
| Omondi, E | 1 |
| Opiyo, E | 1 |
| Bukusi, EA | 1 |
| Cohen, CR | 1 |
| James, JS | 2 |
| Tascini, C | 1 |
| Ferranti, S | 1 |
| Gemignani, G | 1 |
| Messina, F | 1 |
| Menichetti, F | 2 |
| Hermann, W | 1 |
| Günther, P | 1 |
| Berrouschot, J | 1 |
| Kühn, HJ | 1 |
| Wagner, A | 1 |
| King, MD | 1 |
| Perlino, CA | 1 |
| Cinnamon, J | 1 |
| Jernigan, JA | 1 |
| Hossain, MA | 1 |
| Mukherjee, PK | 1 |
| Reyes, G | 1 |
| Long, L | 1 |
| Ghannoum, MA | 2 |
| Liu, Z | 1 |
| Qin, S | 1 |
| Sheng, R | 1 |
| Ross, JJ | 1 |
| Katz, JD | 1 |
| Fonseca, EM | 1 |
| Nuño, FJ | 1 |
| García-Alcalde, ML | 1 |
| Menéndez, MJ | 1 |
| Mootsikapun, P | 2 |
| Anunnatsiri, S | 1 |
| Choksawadphinyo, K | 1 |
| Assing, K | 1 |
| Birgens, H | 1 |
| Arendrup, M | 1 |
| Liou, J | 1 |
| Chiu, C | 1 |
| Tseng, C | 1 |
| Chi, C | 1 |
| Fu, L | 1 |
| Momoff, N | 1 |
| Parrish, A | 2 |
| Iyer, RS | 1 |
| Banker, DD | 1 |
| Rodero, L | 1 |
| Rodriguez, AC | 1 |
| Salve, A | 1 |
| Cuenca-Estrella, M | 1 |
| Rodriguez-Tudela, JL | 1 |
| Schell, WA | 2 |
| Wills, EA | 1 |
| Boyce, M | 1 |
| Benjamin, DK | 1 |
| Bartroli, J | 1 |
| Bauer, M | 6 |
| Thomas, AM | 4 |
| John, L | 1 |
| Nelson, M | 1 |
| Thinkhamrop, B | 1 |
| Boonyaprawit, P | 1 |
| Rajanuwong, A | 1 |
| Griffin, GE | 1 |
| Sar, B | 1 |
| Monchy, D | 1 |
| Vann, M | 1 |
| Keo, C | 1 |
| Sarthou, JL | 1 |
| Buisson, Y | 1 |
| Panomvana Na Ayudhya, D | 1 |
| Thanompuangseree, N | 1 |
| Tansuphaswadikul, S | 2 |
| Lane, M | 1 |
| McBride, J | 1 |
| Archer, J | 1 |
| Leite, AG | 1 |
| Bonasser Filho, F | 1 |
| Nogueira, RS | 1 |
| Oliveira, AC | 1 |
| Sabbatani, S | 1 |
| Manfredi, R | 1 |
| Pavoni, M | 1 |
| Consales, A | 1 |
| Chiodo, F | 1 |
| Miyoshi, T | 1 |
| Hasegawa, T | 1 |
| Tago, H | 1 |
| Nakashima, I | 1 |
| Shiga, Y | 1 |
| Kikuchi, T | 1 |
| Higano, S | 1 |
| Itoyama, Y | 1 |
| Martínez-Baltanás, A | 1 |
| Cuadrado, JM | 1 |
| Jover, F | 1 |
| Roig, P | 2 |
| Chotmongkol, V | 1 |
| Arayawichanont, A | 1 |
| Sawanyawisuth, K | 1 |
| Thavornpitak, Y | 1 |
| Othman, N | 1 |
| Abdullah, NA | 1 |
| Wahab, ZA | 1 |
| Woodworth, GF | 1 |
| McGirt, MJ | 1 |
| Williams, MA | 1 |
| Rigamonti, D | 1 |
| Shinjoh, M | 1 |
| Miyairi, I | 1 |
| Sakurai, M | 1 |
| Takahashi, M | 1 |
| Ariyasu, D | 1 |
| Nakayama, T | 2 |
| Tokumura, M | 1 |
| Yamashita, R | 1 |
| Sunakawa, K | 1 |
| Takahashi, T | 1 |
| de Górgolas, M | 1 |
| Erice, A | 1 |
| Gil, A | 1 |
| Gutiérrez, J | 1 |
| Rivas, P | 1 |
| Hernando, C | 1 |
| Rodríguez, MC | 1 |
| Chang, LW | 1 |
| Phipps, WT | 1 |
| Kennedy, GE | 1 |
| Rutherford, GW | 1 |
| Sanchez, A | 1 |
| Citron, D | 1 |
| Rathbun, M | 1 |
| Ho, TL | 1 |
| Lee, HJ | 1 |
| Lee, KW | 1 |
| Chen, WL | 1 |
| Torfoss, D | 1 |
| Sandven, P | 1 |
| Lawn, SD | 1 |
| Myer, L | 1 |
| Orrell, C | 1 |
| Macsween, KF | 1 |
| Marsh, H | 1 |
| Macallan, DC | 1 |
| Vakis, A | 1 |
| Koutentakis, D | 1 |
| Karabetsos, D | 1 |
| Ntouros, D | 1 |
| Skiest, DJ | 1 |
| Hester, LJ | 1 |
| Hardy, RD | 1 |
| Gibold, X | 1 |
| Husson, A | 1 |
| Corbain, V | 1 |
| Vidal, M | 1 |
| Gourdon, F | 1 |
| Laurichesse, H | 1 |
| Beytout, J | 1 |
| Irthum, P | 1 |
| Ferrier, A | 1 |
| Lesens, O | 1 |
| Yang, CC | 1 |
| Lee, HS | 1 |
| Chen, CC | 1 |
| Cheng, CJ | 1 |
| Lin, SH | 1 |
| Schaars, CF | 1 |
| Meintjes, GA | 1 |
| Morroni, C | 1 |
| Post, FA | 1 |
| Maartens, G | 1 |
| Thongyen, S | 1 |
| Chumpathat, N | 1 |
| Eampokalap, B | 1 |
| Thawornwan, U | 1 |
| Foongladda, S | 1 |
| Khyriem, AB | 1 |
| Sujatha, S | 1 |
| Parija, SC | 1 |
| Niepieklo, A | 1 |
| Dyakopu, N | 1 |
| Hamill, RJ | 2 |
| Maek-a-Nantawat, W | 1 |
| Phonrat, B | 1 |
| Boonpokbn, L | 1 |
| Mctm, AG | 1 |
| Pitisuttithum, P | 1 |
| Tsuchida, H | 1 |
| Ichikawa, D | 1 |
| Shima, Y | 1 |
| Yasuda, T | 1 |
| Sato, T | 1 |
| Kimura, K | 1 |
| Sahraian, MA | 1 |
| Motamedi, M | 1 |
| Azimi, AR | 1 |
| Hasan Paknejad, SM | 1 |
| Collett, G | 1 |
| Wright, P | 1 |
| Inverarity, D | 1 |
| Hayes, M | 1 |
| Sing, Y | 1 |
| Ramdial, PK | 1 |
| Chottanapund, S | 1 |
| Singhasivanon, P | 1 |
| Kaewkungwal, J | 1 |
| Chamroonswasdi, K | 1 |
| Negroni, R | 1 |
| Maiolo, E | 1 |
| Arechavala, AI | 1 |
| Bianchi, MH | 1 |
| Santiso, G | 1 |
| McMahon, JH | 1 |
| Grayson, ML | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Nakamura, S | 1 |
| Izumikawa, K | 1 |
| Seki, M | 1 |
| Fujimoto, K | 1 |
| Mishima, K | 1 |
| Kakeya, H | 1 |
| Yamamoto, Y | 1 |
| Yanagihara, K | 1 |
| Mizuta, Y | 1 |
| Kitaoka, T | 1 |
| Kohno, S | 2 |
| Milefchik, E | 1 |
| Leal, MA | 5 |
| Haubrich, R | 1 |
| Bozzette, SA | 2 |
| Tilles, JG | 2 |
| Leedom, JM | 2 |
| McCutchan, JA | 2 |
| Lecuit, M | 1 |
| Roujeau, T | 1 |
| Renier, D | 1 |
| Bougnoux, ME | 1 |
| Lucas, SB | 1 |
| De Cock, KM | 1 |
| Hay, RJ | 2 |
| L'Her, P | 1 |
| Savuth, C | 1 |
| Than, T | 1 |
| San, KK | 1 |
| Vuthea, KS | 1 |
| Leang, S | 1 |
| Sophouen, N | 1 |
| Arborio, M | 1 |
| Ennis, DM | 1 |
| Saag, MS | 5 |
| de Lalla, F | 1 |
| Pellizzer, G | 1 |
| Vaglia, A | 1 |
| Manfrin, V | 1 |
| Franzetti, M | 1 |
| Fabris, P | 1 |
| Stecca, C | 1 |
| Quagliarello, VJ | 1 |
| Viscoli, C | 1 |
| Horwitz, RI | 1 |
| Jones, BE | 1 |
| Haghighat, D | 1 |
| Forthal, D | 1 |
| Takeda, S | 1 |
| Tatara, I | 1 |
| Kono, K | 1 |
| Arakawa, K | 1 |
| Paugam, A | 1 |
| Dupouy-Camet, J | 1 |
| Blanche, P | 1 |
| Gangneux, JP | 1 |
| Tourte-Schaefer, C | 1 |
| Sicard, D | 1 |
| Ong, CT | 1 |
| Tsai, JJ | 1 |
| La, ML | 1 |
| Ramirez, JA | 1 |
| Srinath, L | 1 |
| Ahkee, S | 1 |
| Huang, AK | 1 |
| Raff, MJ | 1 |
| Nelson, MR | 1 |
| Fisher, M | 1 |
| Cartledge, J | 1 |
| Rogers, T | 1 |
| Gazzard, BG | 1 |
| Cloud, GA | 4 |
| Dismukes, WE | 2 |
| Stevens, DA | 1 |
| Spitzer, ED | 2 |
| Spitzer, SG | 1 |
| Freundlich, LF | 1 |
| Magee, JT | 1 |
| Philpot, C | 1 |
| Yang, J | 1 |
| Hosein, IK | 1 |
| Peetermans, W | 1 |
| Bobbaers, H | 1 |
| Verhaegen, J | 1 |
| Vandepitte, J | 1 |
| Maher, D | 1 |
| Mwandumba, H | 1 |
| Bertucci, R | 1 |
| Leggieri, A | 1 |
| Preziosi, C | 1 |
| Milano, R | 1 |
| Arduino, C | 1 |
| Veglio, V | 1 |
| Webb, D | 1 |
| Rinaldi, MG | 5 |
| Velez, JD | 1 |
| Allendoerfer, R | 1 |
| Luther, M | 1 |
| Ammassari, A | 1 |
| Linzalone, A | 1 |
| Murri, R | 1 |
| Marasca, G | 1 |
| Morace, G | 1 |
| Antinori, A | 1 |
| Kartalija, M | 1 |
| Kaye, K | 1 |
| Tureen, JH | 1 |
| Liu, Q | 1 |
| Täuber, MG | 1 |
| Elliott, BR | 1 |
| Sande, MA | 1 |
| Mathoulin, S | 1 |
| Dupont, B | 3 |
| Brugiere, O | 1 |
| Letenneur, L | 1 |
| Fiorio, M | 1 |
| Tosti, A | 1 |
| Gatti, G | 2 |
| Bruna Pasticci, M | 1 |
| Miletich, F | 1 |
| Marroni, M | 1 |
| Bassetti, D | 1 |
| Pauluzzi, S | 1 |
| Deo, S | 1 |
| Sullivan, D | 1 |
| Haynes, K | 1 |
| Moran, G | 1 |
| Shanley, D | 1 |
| Coleman, D | 1 |
| Inami, T | 1 |
| Tomita, Y | 1 |
| Hashimoto, S | 1 |
| Nishinarita, S | 1 |
| Horie, T | 1 |
| Witt, MD | 1 |
| Lewis, RJ | 1 |
| Milefchik, EN | 1 |
| Haubrich, RH | 1 |
| Richie, JA | 1 |
| Edwards, JE | 1 |
| Cox, GM | 1 |
| Dodge, RK | 1 |
| Weiner, JM | 1 |
| Diamond, DM | 3 |
| Leal, ME | 1 |
| Ding, JC | 3 |
| Yamaguchi, H | 1 |
| Ikemoto, H | 1 |
| Watanabe, K | 2 |
| Ito, A | 1 |
| Hara, K | 1 |
| Singh, N | 1 |
| Barnish, MJ | 1 |
| Berman, S | 1 |
| Bender, B | 1 |
| Wagener, MM | 1 |
| Yu, VL | 1 |
| Armengou, A | 1 |
| Porcar, C | 1 |
| Mascaró, J | 1 |
| García-Bragado, F | 1 |
| Jaruratanasirikul, S | 2 |
| Kleepkaew, A | 1 |
| Clark, AB | 1 |
| Lobo, BL | 1 |
| Barantsevich, EP | 1 |
| Nguyen, MH | 1 |
| Yu, CY | 1 |
| Tuazon, CU | 2 |
| Kerkering, T | 1 |
| Moskovitz, BL | 1 |
| Johnson, D | 2 |
| Williams, BK | 2 |
| Najvar, L | 2 |
| Ferreira, RC | 1 |
| Phan, G | 1 |
| Bateman, JB | 1 |
| Leenders, AC | 1 |
| Reiss, P | 2 |
| Portegies, P | 1 |
| Clezy, K | 1 |
| Hop, WC | 1 |
| Hoy, J | 1 |
| Borleffs, JC | 1 |
| Allworth, T | 1 |
| Kauffmann, RH | 1 |
| Jones, P | 1 |
| Kroon, FP | 1 |
| Verbrugh, HA | 1 |
| de Marie, S | 1 |
| Antony, SJ | 1 |
| Patel, A | 1 |
| Leonard, J | 1 |
| Craig, TJ | 1 |
| Penk, A | 1 |
| Pittrow, L | 1 |
| Daniel, BE | 1 |
| Seaton, RA | 1 |
| Luzzati, R | 1 |
| Lazzarini, L | 1 |
| Limonta, D | 1 |
| Vento, S | 1 |
| Concia, E | 1 |
| Oishi, K | 1 |
| Mitarai, S | 1 |
| Yamashita, H | 1 |
| Nalongo, K | 1 |
| Izumi, T | 1 |
| Augustine, K | 1 |
| Mugerwa, R | 1 |
| Nagatake, T | 1 |
| Matsumoto, K | 1 |
| Biswas, J | 1 |
| Gopal, L | 1 |
| Sharma, T | 1 |
| Parikh, S | 1 |
| Madhavan, HN | 1 |
| Badrinath, SS | 1 |
| Luchi, M | 1 |
| Saberhagen, C | 1 |
| Hinthorn, D | 1 |
| Pfaller, M | 1 |
| Zhang, J | 1 |
| Messer, S | 1 |
| Tumberland, M | 1 |
| Mbidde, E | 1 |
| Jessup, C | 1 |
| Ghannoum, M | 1 |
| Oursler, KA | 1 |
| Moore, RD | 1 |
| Chaisson, RE | 1 |
| Mejri, H | 1 |
| Boussen, N | 1 |
| Kilani, B | 1 |
| Zouiten, F | 1 |
| Ben Abid, H | 1 |
| Zribi, A | 1 |
| Kalita, J | 1 |
| Bansal, R | 1 |
| Ayagiri, A | 1 |
| Misra, UK | 1 |
| Dargél, AA | 1 |
| Chang, WN | 1 |
| Chang, HW | 1 |
| Chuang, YC | 1 |
| Pintado García, V | 1 |
| Martín Dávila, P | 1 |
| Muñoz Labián, V | 1 |
| Quereda Rodríguez-Navarro, C | 1 |
| Giner, V | 1 |
| Casademont, J | 1 |
| Cardellach, F | 1 |
| Lee, YC | 1 |
| Chew, GT | 1 |
| Robinson, BW | 1 |
| Wong-Beringer, A | 1 |
| Shriner, K | 1 |
| Sidley, P | 1 |
| Kalra, SP | 1 |
| Chadha, DS | 1 |
| Singh, AP | 1 |
| Sanchetee, PC | 1 |
| Mohapatra, AK | 1 |
| Shih, CC | 1 |
| Chen, YC | 1 |
| Chang, SC | 1 |
| Luh, KT | 1 |
| Hsieh, WC | 1 |
| Godwin, TA | 1 |
| Hong, W | 1 |
| Gu, J | 1 |
| Watanabe, H | 1 |
| Inukai, A | 1 |
| Doyu, M | 1 |
| Sobue, G | 1 |
| Restrepo, MI | 1 |
| Barchiesi, F | 1 |
| Luther, MF | 1 |
| Martínez, E | 1 |
| García-Viejo, MA | 1 |
| Marcos, MA | 1 |
| Pérez-Cuevas, JB | 1 |
| Blanco, JL | 1 |
| Mallolas, J | 1 |
| Miró, JM | 1 |
| Gatell, JM | 1 |
| Ford, BJ | 1 |
| Kapoor, A | 1 |
| Flechner, SM | 1 |
| O'Malley, K | 1 |
| Paolone, D | 1 |
| File, TM | 1 |
| Cutrona, AF | 1 |
| Friese, G | 1 |
| Discher, T | 1 |
| Füssle, R | 1 |
| Schmalreck, A | 1 |
| Lohmeyer, J | 1 |
| Mwansa, J | 1 |
| Chintu, C | 1 |
| Pobee, J | 1 |
| Scarborough, M | 1 |
| Portsmouth, S | 1 |
| Zumla, A | 1 |
| Yao, Z | 1 |
| Wen, H | 1 |
| Mocsny, N | 1 |
| Mínguez Castellanos, A | 1 |
| Ortega Moreno, A | 1 |
| Vilches Carrillo, RM | 1 |
| Foronda Bengoa, J | 1 |
| Bhabha, SK | 1 |
| Chowdhary, NK | 1 |
| Agarwal, A | 1 |
| Vivekanand, JH | 1 |
| Das, T | 1 |
| Sakhuja, V | 1 |
| Chugh, KS | 1 |
| Denning, DW | 1 |
| Robinson, P | 2 |
| Meyer, RD | 1 |
| Jacobson, JM | 1 |
| Sugar, AM | 2 |
| McAuliffe, VJ | 1 |
| Follansbee, SE | 1 |
| Coker, RJ | 1 |
| Moulopoulos, D | 1 |
| Main, J | 1 |
| Murphy, SM | 1 |
| Pinching, AJ | 1 |
| Harris, JR | 1 |
| Pradier, C | 1 |
| Bernard, E | 1 |
| Lubick, C | 1 |
| Toussaint-Gari, M | 1 |
| Pinier, Y | 1 |
| Durant, J | 1 |
| Mondain, V | 1 |
| Le Fichoux, Y | 1 |
| Dellamonica, P | 1 |
| Haglund, LA | 1 |
| Greenfield, RA | 1 |
| Carrasco, R | 1 |
| Salavert, M | 1 |
| Nieto, A | 1 |
| Bernacer, B | 1 |
| Navarro, V | 1 |
| Laroche, R | 1 |
| Touze, JE | 1 |
| Taelman, H | 1 |
| Bogaerts, J | 1 |
| Kadio, A | 1 |
| M'Pele, P | 1 |
| Latif, A | 1 |
| Aubry, P | 1 |
| Durbec, JP | 1 |
| Tolins, JP | 1 |
| Pialoux, G | 1 |
| González Quijada, S | 1 |
| Pedrajas Navas, JM | 1 |
| Borregón Carretero, SJ | 1 |
| Téllez Molina, J | 1 |
| Berry, AJ | 1 |
| Gazapo Carretero, E | 1 |
| García Aguado, C | 1 |
| Adrados de Llano, M | 1 |
| Martínez Blanco, ML | 1 |
| Verdejo Ortes, J | 1 |
| González Lahoz, JM | 1 |
| Lange, JM | 1 |
| Williams, KW | 1 |
| Grieco, MH | 1 |
| Sharkey, PK | 1 |
| Thompson, SE | 1 |
| Fisher, JF | 1 |
| Izumoto, S | 1 |
| Nakagawa, H | 1 |
| Fujita, T | 1 |
| Kubo, S | 1 |
| Glück, T | 1 |
| Weber, P | 1 |
| Wiedmann, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| Cryptococcal Antigen Screening Plus Sertraline[NCT03002012] | Phase 3 | 22 participants (Actual) | Interventional | 2017-11-15 | Terminated (stopped due to SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.) | ||
| Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients[NCT05153005] | 600 participants (Anticipated) | Observational | 2021-04-01 | Recruiting | |||
| A Multi-center, Prospective, Randomized Trial of Amphotericin B in the Initial Antifungal Therapy for Non-HIV Cryptococcal Meningitis Patients[NCT06178627] | Phase 4 | 250 participants (Anticipated) | Interventional | 2023-08-13 | Enrolling by invitation | ||
| Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis[NCT01802385] | Phase 3 | 460 participants (Actual) | Interventional | 2015-03-09 | Completed | ||
| A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis[NCT00885703] | Phase 1/Phase 2 | 168 participants (Actual) | Interventional | 2010-04-16 | Completed | ||
| A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis[NCT00145249] | Phase 2 | 143 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.[NCT00830856] | 54 participants (Actual) | Interventional | 2006-10-31 | Completed | |||
| Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis[NCT01075152] | Phase 4 | 177 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.[NCT00002113] | 64 participants | Interventional | Completed | ||||
| Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis[NCT00000708] | 120 participants | Interventional | Completed | ||||
| Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome[NCT00001017] | Phase 3 | 330 participants | Interventional | Completed | |||
| A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis[NCT00000639] | 400 participants | Interventional | Completed | ||||
| Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome[NCT00002074] | 0 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cryptococcal meningitis free survival with retention-in-care through 6 months~Those who die of any cause are failures~Those developing symptomatic cryptococcal meningitis are failures~Those lost to follow up and unable to be tracked are considered failures" (NCT03002012)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 11 |
| Control | 9 |
Survival through 6 months (NCT03002012)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 11 |
| Control | 10 |
Number of participants whose study drug/placebo use was halted prematurely due to any cause through 6 months (NCT03002012)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sertraline | 1 |
| Control | 0 |
Cumulative incidence of symptomatic cryptococcal meningoencephalitis through 6 months (NCT03002012)
Timeframe: 6 months
| Intervention | meningitis events (Number) |
|---|---|
| Sertraline | 0 |
| Control | 1 |
Number of Clinical Adverse Events by Division of AIDS (DAIDS) Scale for Grade 3-5 events through 6 months (NCT03002012)
Timeframe: 6 months
| Intervention | number of grade 3-5 adverse events (Number) |
|---|---|
| Sertraline | 4 |
| Control | 2 |
Number of Laboratory Grade 3-5 Adverse Events through 6 months as per the Division of AIDS (DAIDS) grading scale (NCT03002012)
Timeframe: 6 months
| Intervention | number of grade 3-5 adverse events (Number) |
|---|---|
| Sertraline | 4 |
| Control | 1 |
Participants' percent adherence to study drug regiment by pharmacy medication counts, representing the percent of the total prescribed medication taken by participants. (NCT03002012)
Timeframe: 12 weeks
| Intervention | Percent of total prescribed medication t (Median) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Control | 100 | 100 | 100 | 100 |
| Sertraline | 100 | 100 | 97 | 89 |
Prevalence of depression by Patient Health Questionnaire (PHQ-9) over 6 months as measured at baseline, 4 weeks, 8 weeks, and 12 weeks. The PHQ-9 is a 9-item instrument for screening, diagnosing, monitoring, and measuring the severity of depression. Items are rated on a scale from 0 (not at all) to 3 (nearly every day). Total score is a sum of 9 item scores (Range 0-27). Greater scores indicate greater depressive symptoms. PHQ-9 scores of: 0-4 Minimal/No depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderate severe depression; 20-27 Severe depression. This endpoint reports the median (interquartile range) of the PHQ-9 scores over time. (NCT03002012)
Timeframe: 12 weeks
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| Week 4 | Week 8 | Week 12 | |
| Control | 5 | 3 | 2 |
| Sertraline | 5 | 6 | 2 |
Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 16.6 |
| Sertraline 400mg | 13.2 |
Number of participants with sterile cerebrospinal fluid at 2 weeks (NCT01802385)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 90 |
| Sertraline 400mg | 101 |
Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse. (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 116 |
| Sertraline 400mg | 103 |
Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Sertraline 400mg | 5 |
Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score (Mean) |
|---|---|
| Placebo | -1.4 |
| Sertraline 400mg | -1.3 |
Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions (NCT01802385)
Timeframe: 18 weeks
| Intervention | events (Number) |
|---|---|
| Placebo | 121 |
| Sertraline 400mg | 141 |
18-week survival. The comparison will be between sertraline 400mg group and placebo (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 125 |
| Sertraline 400mg | 109 |
To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone. (NCT01802385)
Timeframe: 14 days
| Intervention | -log10 CFU/ml/day (Mean) | |
|---|---|---|
| General Linear Regression | Mixed-Effects Regression | |
| Placebo | 0.47 | 0.33 |
| Sertraline 400mg | .43 | .33 |
"Change in quantitative CSF (cerebrospinal fluid) cultures.~Note: No further CSF specimens are drawn following a negative culture. Thus, only week 2 CSF cultures are considered in this analysis." (NCT00885703)
Timeframe: Entry and Week 2
| Intervention | Log10 CFU/mL (Median) |
|---|---|
| Fluconazole 1200mg | -1.51 |
| Fluconazole 1600mg | -2.51 |
| Fluconazole 2000mg | -1.78 |
| Ampho B | -2.81 |
Kaplan Meier Proportion of participants who died over study with 90% Confidence Intervals. (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | proportion of participants (Number) |
|---|---|
| Fluconazole 1200mg | 0.41 |
| Fluconazole 1600mg | 0.30 |
| Fluconazole 2000mg | 0.36 |
| Ampho B | 0.24 |
Duration of first hospitalization in days starting at entry in safety population. (NCT00885703)
Timeframe: Measured from study entry through Week 10
| Intervention | Days (Median) |
|---|---|
| Fluconazole 1200mg | 15 |
| Fluconazole 1600mg | 17.5 |
| Fluconazole 2000mg | 18 |
| Ampho B | 18.5 |
"Discontinuation of study-provided high dose fluconazole at or by week 10 Discontinuation of study-provided ampho B at or by week 2~Discontinuation includes discontinuing for any reason, including progression of symptoms, death, etc." (NCT00885703)
Timeframe: Measured from study entry through Week10
| Intervention | Participants (Count of Participants) |
|---|---|
| Stage 1, Fluconazole 1200mg | 14 |
| Stage 1, Fluconazole 1600mg | 11 |
| Stage 1, Fluconazole 2000mg | 11 |
| Stage 1, Ampho B | 6 |
| Stage 2, Fluconazole 1600mg | 12 |
| Stage 2, Fluconazole 2000mg | 13 |
| Stage 2, Ampho B | 6 |
Number of participants who were diagnosed with CNS immune reconstitution inflammatory syndrome (IRIS) (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluconazole 1200mg | 1 |
| Fluconazole 1600mg | 0 |
| Fluconazole 2000mg | 0 |
| Ampho B | 1 |
"Progression of symptoms is defined as:~Died (including early deaths)~Discontinued Fluconazole and started ampho B~Had a positive cryptococcal culture at week 10~Microbiological Failure (i.e., relapse of CM)~Complication of CM (e.g., obstructive hydrocephalus or vascular complications such as venous or arterial thrombosis)~CM IRIS causing increased inflammation after ART exposure~New CNS Ol (e.g., toxoplasmosis, PML, CNS lymphoma)~Possibly related to CM but mechanism indeterminate~Other defined complication unrelated to CM" (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluconazole 1200mg | 14 |
| Fluconazole 1600mg | 21 |
| Fluconazole 2000mg | 24 |
| Ampho B | 19 |
"Occurrence of grade 3 (severe) and 4 (life-threatening) sign and symptoms events (as defined by FSTRF Appendix 29)~Occurrence of grade 3 (severe) and 4 (life-threatening) laboratory events (as defined by FSTRF Appendix 76)~See DAIDS AE Grading table V1.0" (NCT00885703)
Timeframe: Measured from study entry through Week 24
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Sign/Symptom Events | Laboratory Events | |
| Ampho B | 24 | 30 |
| Fluconazole 1200mg | 16 | 12 |
| Fluconazole 1600mg | 23 | 27 |
| Fluconazole 2000mg | 32 | 26 |
"Functional assessment of work status and ability. Consists of 2 measures: 1) Does participants have full time work status 2) Does participant have functional ability to work.~The measure from 6 week before enrollment will be referred to as 'baseline'." (NCT00885703)
Timeframe: Measured 6 weeks before enrollment, at study entry, at Week 10, and at Week 24
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline Had full time work status | Entry Had full time work status | Week 10 Had full time work status | Week 24 Had full time work status | Baseline Had functional ability to work | Entry Had functional ability to work | Week 10 Had functional ability to work | Week 24 Had functional ability to work | |
| Ampho B | 42 | 9 | 13 | 22 | 38 | 7 | 15 | 24 |
| Fluconazole 1200mg | 18 | 3 | 3 | 7 | 16 | 1 | 4 | 7 |
| Fluconazole 1600mg | 41 | 9 | 16 | 18 | 41 | 8 | 18 | 19 |
| Fluconazole 2000mg | 36 | 8 | 9 | 17 | 32 | 3 | 9 | 16 |
Count of participants who were CM negative (had no cryptococcal growth), CM negative after switching treatment (switched from Fluconazole to Ampho B or vice versa and later became CM negative), CM positive, Died, Lost to follow-up. Note: CM positive means continued to have cryptococcal growth. (NCT00885703)
Timeframe: At entry, Week 2, and Week 10
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 072337496 | Week 072337498 | Week 072337499 | Week 072337497 | Week 272337496 | Week 272337497 | Week 272337498 | Week 272337499 | Week 1072337496 | Week 1072337497 | Week 1072337498 | Week 1072337499 | |||||||||||||||||||||||||||||||||||||||||||||||||
| CM Negative after switching treatment | Died | Lost to Follow-up | CM Positive | CM Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1200mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 1600mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluconazole 2000mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ampho B | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Results from Glasgow Coma Score, which provides assessment of impairment of conscious level in response to defined stimuli. Min score of 0 and max score of 15 (no mental impairment). (NCT00885703)
Timeframe: Measured at study entry, Week 2, and Week 10
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 072337496 | Week 072337497 | Week 072337498 | Week 072337499 | Week 272337496 | Week 272337497 | Week 272337498 | Week 272337499 | Week 1072337497 | Week 1072337498 | Week 1072337496 | Week 1072337499 | |||||||||||||
| Score = 15 | Score < 15 | |||||||||||||||||||||||
| Fluconazole 1200mg | 5 | |||||||||||||||||||||||
| Fluconazole 1600mg | 5 | |||||||||||||||||||||||
| Fluconazole 2000mg | 5 | |||||||||||||||||||||||
| Ampho B | 1 | |||||||||||||||||||||||
| Fluconazole 1200mg | 17 | |||||||||||||||||||||||
| Fluconazole 1600mg | 45 | |||||||||||||||||||||||
| Fluconazole 2000mg | 42 | |||||||||||||||||||||||
| Ampho B | 47 | |||||||||||||||||||||||
| Fluconazole 1200mg | 2 | |||||||||||||||||||||||
| Fluconazole 1600mg | 4 | |||||||||||||||||||||||
| Fluconazole 2000mg | 4 | |||||||||||||||||||||||
| Ampho B | 5 | |||||||||||||||||||||||
| Fluconazole 1200mg | 15 | |||||||||||||||||||||||
| Fluconazole 1600mg | 38 | |||||||||||||||||||||||
| Fluconazole 2000mg | 36 | |||||||||||||||||||||||
| Ampho B | 38 | |||||||||||||||||||||||
| Fluconazole 1200mg | 1 | |||||||||||||||||||||||
| Fluconazole 1600mg | 1 | |||||||||||||||||||||||
| Fluconazole 2000mg | 1 | |||||||||||||||||||||||
| Ampho B | 0 | |||||||||||||||||||||||
| Fluconazole 1200mg | 11 | |||||||||||||||||||||||
| Fluconazole 1600mg | 33 | |||||||||||||||||||||||
| Fluconazole 2000mg | 26 | |||||||||||||||||||||||
| Ampho B | 34 | |||||||||||||||||||||||
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 14
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 0.5 |
| AmphoB+Fluc400 | 2.1 |
| AmphoB + Fluc800 | 3.5 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 168
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 2.0 |
| AmphoB+Fluc400 | 2.8 |
| AmphoB + Fluc800 | 4.4 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 42
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 1.6 |
| AmphoB+Fluc400 | 1.8 |
| AmphoB + Fluc800 | 3.3 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 70
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 1.5 |
| AmphoB+Fluc400 | 2.2 |
| AmphoB + Fluc800 | 4.2 |
Mean days of hospitalization. Includes days subject was hospitalized prior to study enrollment for current hospital stay. (NCT00145249)
Timeframe: 7, 14, 42, and 70 days
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 42 | Day 70 | |
| AmphoB + Fluc800 | 8.1 | 13.6 | 16.5 | 16.6 |
| AmphoB Standard | 8.9 | 15.4 | 16.3 | 16.7 |
| AmphoB+Fluc400 | 8.8 | 15.1 | 17.4 | 20.1 |
"Number of deaths occurring on study.~Day = Day relative to the first dose of study drug." (NCT00145249)
Timeframe: 14, 42, and 70 days
| Intervention | Subjects (Number) | ||||
|---|---|---|---|---|---|
| All Deaths | Day 1-14 | Day 15-42 | Day 43-70 | Day >70 | |
| AmphoB + Fluc800 | 9 | 1 | 1 | 5 | 2 |
| AmphoB Standard | 10 | 3 | 3 | 1 | 3 |
| AmphoB+Fluc400 | 8 | 2 | 2 | 2 | 2 |
"Events are reported by MedDRA Preferred Term.~Dose limiting toxicities include events that resulted in study drug being adjusted, interrupted, or discontinued." (NCT00145249)
Timeframe: Day 100
| Intervention | Events (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Events | Blood creatinine increased | Creatinine renal clearance decreased | Creatinine renal clearance increased | Renal failure | Renal failure acute | Azotaemia | Renal impairment | Nausea | Vomiting | Drug intolerance | Chills | Neutropenia | Hepatitis acute | Pneumonia | Dehydration | Respiratory failure | |
| AmphoB + Fluc800 | 14 | 1 | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| AmphoB Standard | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| AmphoB+Fluc400 | 7 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
"Events are reported by MedDRA Preferred Term.~Grade 3 - Severe. Incapacitating; inability to perform usual activities and daily tasks; significantly affects clinical status; requires therapeutic intervention.~Grade 4 - Life-threatening. AE is life-threatening.~Grade 5 - Death. AE causes death." (NCT00145249)
Timeframe: Day 100
| Intervention | Events (Number) | |||||
|---|---|---|---|---|---|---|
| Hypomagnesaemia | Hypokalaemia | Anaemia | Drug intolerance | Creatinine renal clearance increased | Psychotic disorder | |
| AmphoB + Fluc800 | 0 | 1 | 0 | 0 | 1 | 1 |
| AmphoB Standard | 2 | 0 | 1 | 1 | 0 | 0 |
| AmphoB+Fluc400 | 1 | 0 | 1 | 0 | 0 | 0 |
Treatment success is defined as a composite of the 3 mycologic and clinical measures: CSF culture conversion; neurologically stable or improved; and alive (NCT00145249)
Timeframe: 14, 42, and 70 days
| Intervention | Subjects (Number) | ||
|---|---|---|---|
| Day 14 - Success | Day 42 - Success | Day 70 - Success | |
| AmphoB + Fluc800 | 22 | 33 | 32 |
| AmphoB Standard | 19 | 33 | 33 |
| AmphoB+Fluc400 | 13 | 35 | 36 |
"Number of subjects reporting immune reconstitution inflammatory syndrome (IRIS) following treatment.~Day = Day relative to first dose of study drug" (NCT00145249)
Timeframe: 14, 42, and 70 days
| Intervention | Subjects (Number) | |||
|---|---|---|---|---|
| Day 1 through 70 | Day 1-14 | Day 15-42 | Day 43-70 | |
| AmphoB + Fluc800 | 1 | 0 | 0 | 1 |
| AmphoB Standard | 2 | 0 | 1 | 1 |
| AmphoB+Fluc400 | 0 | 0 | 0 | 0 |
Number of subjects that have a negative fungal culture at Baseline, Day 14, Day 42, and Day 70. (NCT00145249)
Timeframe: Baseline, 14, 42, and 70 days
| Intervention | Subjects (Number) | |||
|---|---|---|---|---|
| Baseline - Negative | Day 14 - Negative | Day 42 - Negative | Day 70 - Negative | |
| AmphoB + Fluc800 | 0 | 22 | 36 | 38 |
| AmphoB Standard | 0 | 20 | 35 | 36 |
| AmphoB+Fluc400 | 0 | 13 | 37 | 39 |
46-week survival by time-to-event analysis of all subjects enrolled (NCT01075152)
Timeframe: 46 weeks
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 41 |
| Deferred HIV Therapy | 29 |
Incidence of antiretroviral therapy interruption by >=3 consecutive days (NCT01075152)
Timeframe: 26 weeks
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 5 |
| Deferred HIV Therapy | 1 |
HIV-1 virologic suppression to <400 copies/mL at 26-weeks after enrollment (NCT01075152)
Timeframe: 26 weeks
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 43 |
| Deferred HIV Therapy | 49 |
Incidence of culture positive cryptococcal meningitis relapse (NCT01075152)
Timeframe: 46 weeks
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 2 |
| Deferred HIV Therapy | 8 |
Incidence of cryptococcal-related immune reconstitution inflammatory syndrome through 46 weeks after enrollment. (NCT01075152)
Timeframe: 46 weeks
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 17 |
| Deferred HIV Therapy | 9 |
Intention to treat analysis of 26 week survival of all subjects enrolled. Reported below are the numbers of participants who died by Week 26. (NCT01075152)
Timeframe: 26 weeks from study entry
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 40 |
| Deferred HIV Therapy | 27 |
Incidence of Adverse Events (Grade 3,4,5) through 46-weeks, as defined by the National Institute of Allergy and Infectious Diseases, Division of AIDS toxicity classification scale, version 2009. (NCT01075152)
Timeframe: 46 weeks
| Intervention | participants (Number) |
|---|---|
| Earlier HIV Therapy | 73 |
| Deferred HIV Therapy | 75 |
"Functional status via Karnofsky performance status score at 4, 26, 46 weeks.~Karnofsky Scale:~100 - Normal; no complaints; no evidence of disease. 90 - Able to carry on normal activity; minor signs or symptoms of disease. 80 - Normal activity with effort; some signs or symptoms of disease. 70 - Cares for self; unable to carry on normal activity or to do active work. 60 - Requires occasional assistance, but is able to care for most of his personal needs.~50 - Requires considerable assistance and frequent medical care. 40 - Disabled; requires special care and assistance. 30 - Severely disabled; hospital admission is indicated although death not imminent.~20 - Very sick; hospital admission necessary; active supportive treatment necessary.~10 - Moribund; fatal processes progressing rapidly. 0 - Dead" (NCT01075152)
Timeframe: 46 weeks
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| 4 weeks | 26 weeks | 46 weeks | |
| Deferred HIV Therapy | 70 | 93 | 95 |
| Earlier HIV Therapy | 70 | 93 | 92 |
Microbiologic clearance of cryptococcus as measured by serial quantitative cryptococcal cultures collected at diagnosis through 14 days of amphotericin therapy. The early fungicidal activity (EFA) of the rate of clearance is expressed as log10 colony forming units (CFU) of Cryptococcus neoformans per mL of CSF per day. (NCT01075152)
Timeframe: 4 weeks
| Intervention | log10 CFU/mL/day (Mean) | |
|---|---|---|
| EFA by mixed effects model | EFA by linear regression | |
| Deferred HIV Therapy | -0.31 | -0.35 |
| Earlier HIV Therapy | -0.31 | -0.39 |
Percentage of Participants who died by week 26 based on CSF white blood cell (WBC) count at study entry (time of randomization at a median of 8 days of anti-fungal therapy). (NCT01075152)
Timeframe: 26 weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CSF WBC <5 /mcl (n=33, 31) | CSF WBC >5/mcL (n=42, 40) | |
| Deferred HIV Therapy | 16.1 | 45 |
| Earlier HIV Therapy | 48.5 | 40.5 |
43 reviews available for fluconazole and Meningitis, Cryptococcal
| Article | Year |
|---|---|
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
Topics: Adult; Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; Glucocorticoids; HIV Infections; | 2022 |
An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV Infectio | 2023 |
Cryptococcal meningoencephalitis with Actinomyces odontolyticus sepsis: a case report and literature review.
Topics: Actinomyces; Actinomycosis; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Fluconazole; | 2023 |
New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.
Topics: Amphotericin B; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cryptococcus; Drug Therapy | 2019 |
Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; Cryptococcus neoform | 2020 |
Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis.
Topics: Adult; Africa South of the Sahara; Aged; Amphotericin B; Antifungal Agents; Female; Fluconazole; HIV | 2020 |
Strategies for the diagnosis and management of meningitis in HIV-infected adults in resource limited settings.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Fluconazole; HIV Infections; Humans | 2021 |
Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review.
Topics: Antifungal Agents; Australia; Cryptococcus gattii; Cryptococcus neoformans; Disabled Persons; Flucon | 2018 |
A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; D | 2018 |
Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; CD4 Lymphocyte Count; Chemoprevention; Female; Fl | 2019 |
Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Cause of | 2018 |
Treatment for HIV-associated cryptococcal meningitis.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Developing Countries; Drug A | 2018 |
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
Topics: Africa; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcus neoformans; Developing Countrie | 2019 |
Recent advances in managing HIV-associated cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; HIV Infections; Humans; Meningitis, Cry | 2019 |
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.
Topics: Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Asia; Fluconazole; | 2013 |
Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Coinfection; Drug Therapy, Combination; Fluconazole; Flucytosine; | 2014 |
[Cryptococcal meningitis].
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Female; Fluconazole; Flucyt | 2015 |
Cryptococcus neoformans var. grubii Infection in HIV-Seronegative Patients from Northeast India: Report of Two Cases with Review of Literature.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Base Sequence; Cryptococcus neoformans; Dermat | 2016 |
Physiological Differences in Cryptococcus neoformans Strains
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Resistance, Fungal; Fluconazole; Fu | 2017 |
Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV | 2017 |
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Antihypertensive Agents; Dev | 2008 |
Treatment of cryptococcal meningitis in resource limited settings.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Developing Countries; Fluc | 2009 |
New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 2012 |
Cryptococcal meningitis and sarcoidosis.
Topics: Adult; Brain; Cryptococcus neoformans; Female; Fluconazole; Humans; Meningitis, Cryptococcal; Predni | 2002 |
Cerebral infarction related to cryptococcal meningitis in an HIV-infected patient: case report and literature review.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebral Infarction | 2004 |
Cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 2004 |
Cryptococcal meningitis in an immunocompetent child: a case report and literature review.
Topics: Amphotericin B; Antifungal Agents; Child, Preschool; Cryptococcus neoformans; Female; Fluconazole; H | 2004 |
Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcosis; Fluconazole; Humans | 2005 |
Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid | 2005 |
Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; An | 2005 |
Cryptococcal meningitis in AIDS.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Carbon; Coloring Agents | 1993 |
The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcosis; Fluconazole; Fungemia; Humans | 1994 |
Management of systemic manifestations of fungal disease in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Coccidioidomycosis; Cryptococcosis; Drug Therapy | 1994 |
Cryptococcal meningitis and AIDS.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Clinical Tr | 1993 |
Recent advances in the management of cryptococcal meningitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; | 1996 |
Recent advances in the management of cryptococcal meningitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; | 1996 |
Recent advances in the management of cryptococcal meningitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; | 1996 |
Recent advances in the management of cryptococcal meningitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; | 1996 |
[High-dose therapy with fluconazole > or = 800 mg/day. Review].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Candidiasis, Oral; Dose-Respo | 1997 |
[Treatment of cryptococcosis in patients with acquired immunodeficiency syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Animals; Antifungal Agents; Clinical T | 1995 |
The management of cryptococcal meningitis in Papua New Guinea.
Topics: Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Cause of Death; Drug Combinations; Drug | 1996 |
[The efficacy of sequential treatment with amphotericin B-fluorocytosine and fluconazole in cryptococcal meningitis not associated with AIDS].
Topics: Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combin | 1999 |
[CNS cryptococcosis with idiopathic CD4+ T lymphocytopenia].
Topics: Adult; Antifungal Agents; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Male; Meningiti | 2000 |
Current approach to the acute management of cryptococcal infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp | 2000 |
Cryptococcal meningitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Drug Therapy, Combination; Fluconazole; Flucy | 1992 |
Therapy for cryptococcal meningitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Animals; Fluconazole; Flucytosine; Humans; Menin | 1992 |
43 trials available for fluconazole and Meningitis, Cryptococcal
| Article | Year |
|---|---|
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Therapy, Combination; Female | 2021 |
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Topics: Administration, Oral; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Amphoterici | 2022 |
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combinat | 2023 |
Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Asymptomatic Infe | 2020 |
Antifungal Susceptibility Does Not Correlate With Fungal Clearance or Survival in AIDS-Associated Cryptococcal Meningitis.
Topics: Acquired Immunodeficiency Syndrome; Antifungal Agents; Fluconazole; Flucytosine; Humans; Meningitis, | 2021 |
Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Inflammatory Agents; Antifungal A | 2020 |
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa.
Topics: Administration, Oral; Adult; Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifung | 2018 |
Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis.
Topics: Adult; Africa; Antifungal Agents; Fluconazole; Heart Conduction System; HIV Infections; Humans; Meni | 2018 |
AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
Topics: Africa South of the Sahara; Amphotericin B; Antifungal Agents; Clinical Trials, Phase III as Topic; | 2018 |
Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis.
Topics: Cryptococcus gattii; Cryptococcus neoformans; Drug Resistance, Fungal; Female; Fluconazole; Humans; | 2019 |
Factors affecting mortality among HIV positive patients two years after completing recommended therapy for Cryptococcal meningitis in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cohort Studies; Dru | 2019 |
One-year Mortality Outcomes From the Advancing Cryptococcal Meningitis Treatment for Africa Trial of Cryptococcal Meningitis Treatment in Malawi.
Topics: Antifungal Agents; Fluconazole; Flucytosine; Humans; Malawi; Meningitis, Cryptococcal | 2020 |
AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Botswana; Clinical Protoco | 2015 |
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
Topics: Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coinfection; Cr | 2015 |
Amphotericin B: the higher the dose, the higher the toxicity.
Topics: Amphotericin B; Antifungal Agents; Dose-Response Relationship, Drug; Fluconazole; Flucytosine; HIV I | 2008 |
A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Female; Fluconazole; HIV Infections; | 2009 |
International collaboration between US and Thailand on a clinical trial of treatment for HIV-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Dose-Response Relat | 2010 |
Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients.
Topics: Amphotericin B; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Biologica | 2010 |
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
Topics: Administration, Oral; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebro | 2010 |
Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Female; Fluconazol | 2010 |
Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid | 2012 |
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; AIDS-Related Opportunistic In | 2012 |
The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; | 2003 |
Cryptococcal meningitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcus neofor | 2002 |
A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Double-Blind Method; Female; | 2004 |
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antigens, Fungal; C | 2004 |
Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibiotics, Antitubercular; Antifungal Agents; Area Unde | 2004 |
Initial treatment of cryptococcal meningitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcus neofor | 2005 |
Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Do | 2006 |
Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cohort Studie | 2008 |
Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcosis; Female; Fluconazole; F | 1995 |
Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cerebrospinal Fluid; Cryptococcus neoformans; Drug The | 1994 |
Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antigens, Fungal; Biomarkers; | 1994 |
Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antigens, Fungal; Biomarkers; | 1994 |
Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antigens, Fungal; Biomarkers; | 1994 |
Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis.
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Amphotericin B; Antigens, Fungal; Biomarkers; | 1994 |
High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Cryptococcu | 1996 |
Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis, Chronic Mucocutan | 1996 |
Lack of effect of fluconazole on the pharmacokinetics of rifampicin in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antifungal Agents; Drug A | 1996 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Double-Blind | 1997 |
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.
Topics: Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti | 1997 |
Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Therapy, Combination; Female; | 1998 |
Antifungal therapy for treatment of cryptococcal meningitis.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Child; Child, Preschool; Cryptococcus neoforma | 2000 |
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amphotericin B; Female; Fluconazole | 1992 |
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amphotericin B; Female; Fluconazole | 1992 |
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amphotericin B; Female; Fluconazole | 1992 |
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amphotericin B; Female; Fluconazole | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Aged; Amphotericin B; Female; Fluco | 1992 |
271 other studies available for fluconazole and Meningitis, Cryptococcal
| Article | Year |
|---|---|
New guinea pig model of Cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Cerebrospinal Fluid; Colony Count, Microbial; Cryptococcus neoformans; D | 2007 |
Discovery of Carboline Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcal Meningitis.
Topics: Animals; Antifungal Agents; Blood-Brain Barrier; Brain; Carbolines; Colony Count, Microbial; Cryptoc | 2019 |
Discovery of Novel Sertraline Derivatives as Potent Anti-
Topics: Antidepressive Agents; Antifungal Agents; Cryptococcus; Cryptococcus neoformans; Humans; Meningitis, | 2022 |
Autoimmune diseases in HIV-negative cryptococcal meningitis.
Topics: Antifungal Agents; Autoimmune Diseases; Fluconazole; HIV Infections; Humans; Meningitis, Cryptococca | 2021 |
Cryptococcal meningitis in patients with and without acquired immunodeficiency.
Topics: Acquired Immunodeficiency Syndrome; Fluconazole; Humans; Meningitis, Cryptococcal | 2022 |
Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries.
Topics: Amphotericin B; Animals; Antifungal Agents; Antigens, Fungal; CD4 Lymphocyte Count; Cost-Benefit Ana | 2022 |
Parkinsonism and prolonged cognitive decline as a manifestation of cryptococcal meningitis in a renal transplant patient.
Topics: Aged; Cognitive Dysfunction; Cryptococcosis; Cryptococcus neoformans; Fluconazole; Humans; Kidney Tr | 2022 |
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa.
Topics: Africa; AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Therapy, Combination; Flucona | 2022 |
Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
Topics: Adult; Antifungal Agents; Cross-Sectional Studies; Cryptococcosis; Female; Fluconazole; Flucytosine; | 2022 |
Amphotericin B plus fluorocytosine combined with voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; Humans; Hypo | 2022 |
Single-Dose Amphotericin B for Cryptococcal Meningitis.
Topics: Amphotericin B; Fluconazole; Flucytosine; Humans; Meningitis, Cryptococcal | 2022 |
Single-Dose Amphotericin B for Cryptococcal Meningitis. Reply.
Topics: Amphotericin B; Fluconazole; Flucytosine; Humans; Meningitis, Cryptococcal | 2022 |
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Topics: Amphotericin B; Antifungal Agents; Cohort Studies; Deoxycholic Acid; Drug Combinations; Drug Therapy | 2022 |
Access to Medicines for Treating People With Cryptococcal Meningitis.
Topics: Antifungal Agents; Drug Administration Schedule; Drug Therapy, Combination; Fluconazole; Health Serv | 2023 |
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda.
Topics: Antifungal Agents; Botswana; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV Infections; Hu | 2022 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
[Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali].
Topics: Acetaminophen; Adolescent; AIDS-Related Opportunistic Infections; Communicable Diseases; Cryptococco | 2022 |
Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis.
Topics: Animals; Antifungal Agents; Cryptococcus neoformans; Fluconazole; Mammals; Meningitis, Cryptococcal; | 2023 |
A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis.
Topics: Acetazolamide; Animals; Antifungal Agents; Cryptococcus neoformans; Fluconazole; Humans; Meningitis, | 2023 |
Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Brain; Cerebrospinal Fluid; Female; Fluconazole; HIV Infec | 2019 |
[Forty cases of neuromeningeal cryptococcosis diagnosed at the Mycology-Parasitology Department of the Ibn Sina hospital in Rabat, over a 21-year period].
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcus | 2019 |
Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
Topics: Adult; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcosis; Cryptococcus; Cryptococcus ne | 2019 |
Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.
Topics: Amphotericin B; Antifungal Agents; Biomarkers; Cerebrospinal Fluid; Fluconazole; HIV Infections; Hum | 2020 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal | 2020 |
Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Cross-Sectional S | 2020 |
The Added Value of Longitudinal Imaging for Preclinical
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Disease Models, | 2020 |
Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Anti-Inflammatory Agents; Anti-Retroviral Agents | 2020 |
Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections.
Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Drug Antagonism; Drug Evaluatio | 2020 |
Cryptococcal meningitis in an immunocompetent patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Culture Techniques; Delayed Diagnosis; Fluconazole; Flucyt | 2020 |
Cryptococcal Meningitis: A Rare Complication in HIV-Negative Patients with Nephrotic Syndrome in A Chinese Teaching Hospital.
Topics: Antifungal Agents; China; Fluconazole; HIV Infections; Hospitals, Teaching; Humans; Meningitis, Cryp | 2020 |
Treatment and mortality outcomes in patients with other extrapulmonary cryptococcal disease compared with central nervous system disease.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Central Nervous System Diseases; Cryptococcosis; Cry | 2021 |
Trehalose as quantitative biomarker for in vivo diagnosis and treatment follow-up in cryptococcomas.
Topics: Amphotericin B; Animals; Biomarkers; Cryptococcus neoformans; Deoxycholic Acid; Drug Combinations; F | 2021 |
Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Therapy, Combination; Female | 2020 |
HIV-Associated Cryptococcal Meningitis Patients Treated with Amphotericin B Deoxycholate Plus Flucytosine under Routine Care Conditions in a Referral Center in São Paulo, Brazil.
Topics: Adult; Amphotericin B; Antifungal Agents; Brazil; Deoxycholic Acid; Drug Combinations; Drug Therapy, | 2021 |
Outcomes in Previously Healthy Cryptococcal Meningoencephalitis Patients Treated With Pulse Taper Corticosteroids for Post-infectious Inflammatory Syndrome.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Cryptococcus; Fluconazole; Humans; Meningitis, Cryptococ | 2021 |
Ambulatory induction phase treatment of cryptococcal meningitis in HIV integrated primary care clinics, Yangon, Myanmar.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Inf | 2021 |
Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
Topics: Adult; Antifungal Agents; Antigens, Fungal; Cryptococcus; Female; Fluconazole; HIV Infections; Human | 2021 |
Topics: Adult; Antifungal Agents; Cysts; Fluconazole; Humans; Immunocompromised Host; Immunosuppressive Agen | 2021 |
Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Colony Count, Micro | 2017 |
Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.
Topics: Adult; Antigens, Fungal; Argentina; Female; Fluconazole; HIV Infections; Humans; Immunoassay; Male; | 2017 |
Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Cryptococcus neoforman | 2017 |
Central nervous system infection due to Cryptococcus gattii sensu lato in India: Analysis of clinical features, molecular profile and antifungal susceptibility.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Central Nervous System Fungal Infections | 2017 |
Cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Brain; Cryptococcus gattii; Cryptococcus neoformans; Deoxycholic | 2017 |
What Is Your Neurologic Diagnosis?
Topics: Amphotericin B; Animals; Anti-Inflammatory Agents; Antifungal Agents; Blindness; Cat Diseases; Cats; | 2017 |
Necrotic ulcer on the thigh.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Diagnosis, Differential; Fluconaz | 2017 |
Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Brazil; Child | 2018 |
Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Cryptococcus; Eth | 2017 |
High-Dose Fluconazole Consolidation Therapy for Cryptococcal Meningitis in Sub-Saharan Africa: Much to Gain, Little to Lose.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Antifungal Agents; Fluconazole; H | 2018 |
A Rare Presentation of Cryptococcal Meningitis and Cerebellitis in an Asplenic Patient, Seronegative for Human Immunodeficiency Virus (HIV).
Topics: Aged; Amphotericin B; Antifungal Agents; Cerebellar Diseases; Cryptococcus neoformans; Diagnosis, Di | 2018 |
A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
Topics: Adult; Antifungal Agents; Antigens, Fungal; Asymptomatic Diseases; CD4 Lymphocyte Count; Cryptococco | 2018 |
Triple therapy versus amphotericin B plus flucytosine for the treatment of non-HIV- and non-transplant-associated cryptococcal meningitis: retrospective cohort study.
Topics: Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Female; Fluconazole; Flucytosin | 2018 |
Bilateral Asymptomatic Cryptococcal Retinitis without Choroiditis or Vitritis.
Topics: Administration, Oral; Adult; Amphotericin B; Antifungal Agents; Choroiditis; Cryptococcosis; Cryptoc | 2018 |
Intracranial Cryptococcoma-Clinicopathologic Correlation and Surgical Outcome: A Single-Institution Experience.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus gattii; Female; Fluconazole; Humans; Im | 2018 |
Multifocal verrucous plaques in an apparently immunocompetent female.
Topics: Adult; Amphotericin B; Antifungal Agents; Dermatomycoses; Female; Fluconazole; Hand Dermatoses; Huma | 2018 |
Cryptococcal meningitis in a previously healthy child.
Topics: Antifungal Agents; Child; Female; Fluconazole; Humans; Meningitis, Cryptococcal; Treatment Outcome | 2017 |
The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.
Topics: 14-alpha Demethylase Inhibitors; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans | 2018 |
A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Fluconazole; Health Pers | 2018 |
Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Brain Ischemia; Cryptococcus neofor | 2018 |
Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Female; Fluconazo | 2019 |
Updating guidance for preventing and treating cryptococcal disease: how evidence and decisions interface.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Anti | 2018 |
High dose fluconazole in salvage therapy for HIV-uninfected cryptococcal meningitis.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; China; Dose-Response Relationship, Drug; | 2018 |
CRYPTOCOCCAL meningitis in a HIV negative newly diagnosed diabetic patient: a CASE report.
Topics: Adult; Antifungal Agents; Cryptococcus neoformans; Diabetes Mellitus; Female; Fluconazole; HIV Seron | 2019 |
Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis.
Topics: Africa; Antifungal Agents; Cost-Benefit Analysis; Fluconazole; Flucytosine; Humans; Meningitis, Cryp | 2020 |
Fluconazole plus flucytosine is a good alternative therapy for non-HIV and non-transplant-associated cryptococcal meningitis: A retrospective cohort study.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus; Deoxycholic Acid; Drug Combinations; Drug Th | 2019 |
Rare presentation of cryptococcal meningitis in an immunocompetent patient.
Topics: Agricultural Workers' Diseases; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Diplopia | 2019 |
The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Synergism; Estrogen Antagonists; Fl | 2019 |
Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
Topics: Antigens, Fungal; CD4 Lymphocyte Count; Cohort Studies; Cryptococcus; Fluconazole; HIV Infections; H | 2020 |
Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antifungal Agents; Antigens, Fungal; Brazil; Cryptococcus | 2019 |
In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Cross | 2012 |
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Topics: Animals; Antifungal Agents; Area Under Curve; Cryptococcus neoformans; Disease Models, Animal; Fluco | 2013 |
Treating cryptococcal meningitis in people with HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 2013 |
Simultaneous cryptococcal and tuberculous meningitis in a patient with systemic lupus erythematosus.
Topics: Administration, Intravenous; Amphotericin B; Antifungal Agents; Antitubercular Agents; Female; Fluco | 2016 |
A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi.
Topics: Adolescent; Adult; Antifungal Agents; Female; Fluconazole; HIV Infections; Humans; Induction Chemoth | 2013 |
Cryptococcal meningitis presenting as sinusitis in a renal transplant recipient.
Topics: Antifungal Agents; Cryptococcus neoformans; Diagnosis, Differential; Female; Fluconazole; Humans; Im | 2013 |
Comparisons of presentations and outcomes of cryptococcal meningitis between patients with and without hepatitis B virus infection.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anti-Infective Agents; Child; Cryptococcus; Female; Flucona | 2014 |
Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study.
Topics: Administration, Intravenous; Adult; Antifungal Agents; Disease Management; Female; Fluconazole; HIV | 2014 |
Cryptococcal meningitis post autologous stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; Humans; Immunosuppressive Agents | 2014 |
Clinical presentation and diagnosis of toxoplasmic encephalitis in Japan.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antifungal Agents; Antiprotozoal Agents; Brain; Central N | 2014 |
Cryptococcal meningitis caused by Cryptococcus neoformans in an immunocompetent soldier.
Topics: Antifungal Agents; Cryptococcus neoformans; Diagnosis, Differential; Drug Therapy, Combination; Fluc | 2014 |
A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Female; Fluconazole; HIV-1; Humans; | 2014 |
Pulmonary cryptococcosis with endobronchial lesions and meningitis.
Topics: Amphotericin B; Animals; Bronchi; Bronchoscopy; Columbidae; Cryptococcosis; Cryptococcus neoformans; | 2014 |
Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Antifungal Agents; Birds; Cameroon; Cry | 2015 |
Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, H | 2015 |
Hidden in a headache: cryptococcal meningitis in a septuagenarian.
Topics: Aged; Amphotericin B; Antifungal Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; | 2015 |
Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral The | 2016 |
[Cryptococcal meningitis and bone tuberculosis in an immunocompetent: a case].
Topics: Adult; Antitubercular Agents; Fluconazole; Humans; Immunocompetence; Male; Meningitis, Cryptococcal; | 2015 |
Voriconazole: a novel treatment option for cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Carbon; China; Cryp | 2015 |
Management of cryptococcal meningitis in a district hospital in KwaZulu-Natal: a clinical audit.
Topics: Adult; Amphotericin B; Antifungal Agents; Female; Fluconazole; Flucytosine; Hospitals, Urban; Humans | 2014 |
Cryptococcus uniguttulatus Meningitis.
Topics: Administration, Intravenous; Aged; Amphotericin B; Antifungal Agents; Cryptococcus; Drug Substitutio | 2015 |
[Successful treatment for cryptococcal meningoencephalitis complicated by cerebral salt-wasting syndrome in a patient with chronic lymphocytic leukemia: A clinical case].
Topics: Aged; Amphotericin B; Antifungal Agents; Comorbidity; Fluconazole; Humans; Hyponatremia; Leukemia, L | 2015 |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Argentina; Cryptococcosis; | 2016 |
[Multiple facial nodules revealing disseminated cryptococcosis in an immunocompetent patient].
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus gattii; Facial Dermatoses; Fa | 2016 |
Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cost-Benefit Analysis; Deo | 2016 |
Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus; Crypto | 2017 |
[Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast].
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cote d'Ivoire; Dose-Response Relati | 2017 |
False impressions from clear cerebrospinal fluid and a normal computed tomography scan: the pressure is still on for a diagnosis.
Topics: Adult; Antifungal Agents; Cerebrospinal Fluid; Confusion; Fluconazole; Humans; Immunocompetence; Mal | 2008 |
Cryptococcus meningitis and skin lesions in an HIV negative child.
Topics: Amphotericin B; Antifungal Agents; Child, Preschool; Cryptococcus neoformans; Drug Therapy, Combinat | 2008 |
Treatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazole.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Blood; Cerebrospinal F | 2008 |
Review of risk factors in four cases of cryptococcosis after heart transplantation.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Drug Therapy, Combinatio | 2008 |
[Neuromeningeal cryptococcosis in non-HIV patients to CHU ward of Point G in Bamako (Mali): 3 case report].
Topics: Adult; Amphotericin B; Antifungal Agents; Ceftriaxone; Cryptococcus neoformans; Fatal Outcome; Fluco | 2008 |
[Neuromeningeal cryptococcosis in patients apparently non-immunodeficient: report of 3 cases in Dakar, Senegal].
Topics: Adult; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Fatal Outcome; Female; Fluconazole; | 2008 |
Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebrospinal Fluid; Colony Count, | 2008 |
Evaluation of the Neo-Sensitabs diffusion method for determining the antifungal susceptibilities of Cryptococcus gattii isolates, using three different agar media.
Topics: Agar; Amphotericin B; Antifungal Agents; Cryptococcus; Culture Media; Diffusion; Drug Resistance, Fu | 2008 |
Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
Topics: Amphotericin B; Antifungal Agents; Child; Cryptococcus; Drug Resistance, Multiple, Fungal; Drug Syne | 2008 |
[Cryptococcal meningoencephalitis related to HIV infection with resistance to fluconazole, relapse, and IRIS].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Cryptococcus neofo | 2009 |
Burden of cryptococcal meningitis in Malawi.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcus neoformans; Fluconazole; HIV | 2009 |
Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifunga | 2009 |
[Twenty-two cases of neuromeningeal cryptococcosis in Tunisia].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Comorbidity; Female | 2009 |
Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Clinical Trials as Topic; Fluconazole; HIV Infections; Humans; Me | 2009 |
Mucocutaneous histoplasmosis in HIV with an atypical ecthyma like presentation.
Topics: Adult; Agricultural Workers' Diseases; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; | 2009 |
Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitis.
Topics: Antifungal Agents; Fluconazole; Heart Conduction System; HIV Infections; Humans; Meningitis, Cryptoc | 2009 |
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebrospinal Fluid; Cohort Studies | 2009 |
[Cryptococcus neoformans meningoencephalitis in immunocompetent schoolchildren].
Topics: Amphotericin B; Animals; Animals, Domestic; Antifungal Agents; Blindness; Cerebrospinal Fluid; Child | 2009 |
Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV | 2009 |
[Cryptococcal meningitis with a fatal outcome in an immunocompetent adult].
Topics: Amphotericin B; Antifungal Agents; Combined Modality Therapy; Drainage; Drug Therapy, Combination; F | 2010 |
The role of an Ommaya reservoir in the management of children with cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Child; Cryptococcus neoformans; Drug Delivery Systems; Female; Fl | 2010 |
Cryptococcal meningitis with an antecedent cutaneous Cryptococcal lesion.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Carbon; Coloring Agents; Cryptococcosis; Cryptococcus | 2009 |
The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
Topics: Amino Acid Sequence; Amphotericin B; Animals; Antifungal Agents; Antimicrobial Cationic Peptides; Co | 2010 |
Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.
Topics: Adult; Amphotericin B; Antifungal Agents; Female; Fluconazole; Humans; Male; Meningitis, Cryptococca | 2010 |
Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis.
Topics: Adult; Antifungal Agents; Female; Fluconazole; HIV Infections; Humans; Male; Meningitis, Cryptococca | 2010 |
Safety, censoring, and intent-to-treat analysis: dangers to generalizability.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Alanine Transaminase; Anti-HIV Agent | 2010 |
Cryptococcus gattii infection in a Spanish pet ferret (Mustela putorius furo) and asymptomatic carriage in ferrets and humans from its environment.
Topics: Amplified Fragment Length Polymorphism Analysis; Animals; Anti-Inflammatory Agents; Antifungal Agent | 2011 |
Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Delivery of Health | 2011 |
[Cryptococcal meningitis in children: description of 3 cases].
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Child; Crypto | 2011 |
Cryptococcal meningitis in immunocompetent children.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Antigens, Fungal; Child; Child, Preschool; Cryptococc | 2012 |
Poor long-term outcomes for cryptococcal meningitis in rural South Africa.
Topics: Adult; Amphotericin B; Antifungal Agents; Female; Fluconazole; HIV Infections; Humans; Male; Meningi | 2011 |
Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients.
Topics: Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Fluconazole; HIV Infections; Humans; Meningi | 2011 |
Measurement of antifungal drug levels in cerebrospinal fluid for cryptococcal meningoencephalitis.
Topics: Aged; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Fluconazole; Humans; Male; Meningi | 2012 |
[Neuromeningeal cryptococcosis and AIDS: an 11-case series from Libreville, Gabon].
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Female; Fluconazole; H | 2010 |
A retrospective study of AIDS-associated cryptomeningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Age Distribution; AIDS-Related Opportunistic Infections; | 2012 |
Auditory neuropathy secondary to cryptococcal central nervous system infection in 2 immunocompromised patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Anti-HIV Agents | 2012 |
Responding to the evidence for improved treatment for cryptococcal meningitis in resource-limited settings.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents | 2012 |
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis.
Topics: Africa; Amphotericin B; Antifungal Agents; Cost-Benefit Analysis; Fluconazole; Flucytosine; Humans; | 2012 |
Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Cr | 2012 |
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Deoxycholic Aci | 2013 |
Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.
Topics: Antifungal Agents; Cryptococcus neoformans; Fluconazole; Humans; Meningitis, Cryptococcal; Polymeras | 2012 |
Two rare cases of central nervous system opportunistic mycoses.
Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillus nidulans; Cryptococcus neoformans; Female; Flu | 2012 |
The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antifungal Agents; Antigens, F | 2013 |
South Africa: historic "defiance campaign" imports generic fluconazole.
Topics: Antifungal Agents; Candidiasis; Drug Costs; Drug Industry; Drugs, Generic; Fluconazole; Humans; Inte | 2000 |
Clinical microbiological case: fever and headache in a heavy consumer of eucalyptus extract.
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Eucalyptus; Fever; Fluconazole; Headache | 2002 |
Cryptococcal meningitis in a patient with systemic immunosuppression 13 years after liver transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; Germa | 2002 |
Paradoxical recurrent meningitis following therapy of cryptococcal meningitis: an immune reconstitution syndrome after initiation of highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antifungal Agents; Antiretroviral Therapy, Highly Active; | 2002 |
Effects of fluconazole singly and in combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal meningoencephalitis in an intracranial murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Cryptococcus neoformans; Disease Models, Animal; | 2002 |
[A clinical study of 26 cases of cryptococcal meningitis].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Amphotericin B; Child; Cryptococcus; Drainage | 2002 |
[Infection due to herpes zoster and cryptococcus after initiating high-activity antiretroviral treatment].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; | 2003 |
Cryptococcus neoformans var neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia.
Topics: Aged; Antifungal Agents; Cryptococcus neoformans; Drug Resistance, Fungal; Fluconazole; HIV Seronega | 2003 |
Cryptococcal meningitis in pediatric systemic lupus erythematosus.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Female; Fluconazole; Humans; | 2003 |
Fluconazole-resistant cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Cryptococcus neoforman | 2003 |
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amino Acid Sequence; Amino Acid Substitution; Antifungal | 2003 |
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Colony Count, Microbial; Cryptococcus neoformans; Fluconazole; Meningiti | 2004 |
Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.
Topics: Amphotericin B; Animals; Antifungal Agents; Body Weight; Brain; Colony Count, Microbial; Cryptococcu | 2004 |
Primary prophylaxis for cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Fluconazole; Humans; Meningitis, Cryptococ | 2004 |
Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cambodia; Cryptococcus neo | 2004 |
Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis.
Topics: Acetazolamide; Adult; Amphotericin B; Antifungal Agents; Arachnoiditis; Cerebral Infarction; Dexamet | 2004 |
Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure.
Topics: Antifungal Agents; Brain Abscess; Chronic Disease; Cryptococcus neoformans; Fluconazole; HIV Seroneg | 2004 |
[A case of cryptococcal meningitis presenting initially as bilateral hearing loss].
Topics: Antifungal Agents; Fluconazole; Gadolinium; Hearing Loss, Bilateral; Humans; Magnetic Resonance Imag | 2004 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; An | 2005 |
The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Dr | 2005 |
Cryptococcal meningitis in an immunocompetent child.
Topics: Antifungal Agents; Cerebrospinal Fluid; Child; Cryptococcus neoformans; Fluconazole; Humans; Immunoc | 2005 |
Cryptococcal meningitis in a patient with X-linked hyper-IgM1 syndrome.
Topics: Adult; Amphotericin B; Antifungal Agents; Deoxycholic Acid; Drug Combinations; Fluconazole; Genetic | 2005 |
Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Cryptococcus neoformans; Disease Models, Animal; Dose-Response Relations | 2005 |
Diffusion-weighted and conventional magnetic resonance imaging in cerebral cryptococcoma.
Topics: Amphotericin B; Antifungal Agents; Brain; Brain Edema; Brain Mapping; Cryptococcus neoformans; Diagn | 2005 |
Invasive fungal infections at The Norwegian Radium Hospital 1998-2003.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cancer Care Facilities; Ca | 2005 |
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antifungal Agents; Female; Flu | 2005 |
Intracerebral CSF collection mimicking cerebral abscess in a patient suffering from cryptococcal meningitis.
Topics: Acyclovir; Aged; Amphotericin B; Anti-Infective Agents; Brain Abscess; Ceftriaxone; Cerebrospinal Fl | 2005 |
[Cryptococcal meningitis disclosed by visual loss in HIV negative patient with ventriculo-atrial shunting].
Topics: Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Blindness; Cerebrospinal Fluid Shunts; | 2006 |
Syndrome of inappropriate antidiuretic hormone secretion in a patient with cryptococcal meningoencephalitis: a hidden mediastinal small cell carcinoma.
Topics: Carcinoma, Small Cell; Cisplatin; Etoposide; Fluconazole; Humans; Hyponatremia; Inappropriate ADH Sy | 2006 |
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; | 2006 |
Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cry | 2006 |
Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Resistance, Fungal; Fluconazole; Hu | 2006 |
Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Resistance, Fungal; F | 2006 |
Free fluconazole for cryptococcal meningitis: too little of a good thing?
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiretroviral Therapy, Hi | 2006 |
[A case of cryptococcal meningitis with nephrotic syndrome and renal insufficiency under immunosuppressive therapy].
Topics: Aged; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Cyclosporine; Drug Administration | 2007 |
Bilateral pulvinar thalamic calcification in a patient with chronic cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Calcinosis; Fluconazole; Hearing Loss; Humans; Hydrocephal | 2007 |
Fluconazole donation and outcomes assessment in cryptococcal meningitis.
Topics: Adult; Anti-Retroviral Agents; Antifungal Agents; Fluconazole; Gift Giving; Humans; Meningitis, Cryp | 2007 |
Human immunodeficiency virus (HIV) related cryptococcal meningitis in rural central Thailand--treatment difficulties and prevention strategies.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2007 |
Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Biomedical Research; Cryp | 2007 |
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Retroviral Agents; Drug Therapy, | 2007 |
Cryptococcal inflammatory pseudotumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcus neoformans; Female; Fl | 2007 |
Survival time of HIV-infected patients with cryptococcal meningitis.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; CD4 Lymphocyte Count; Comorbidity; Female; Fluconazole | 2007 |
[Clinical cases in medical mycology. Case no. 32].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Bacteremia; Bronchoalveolar | 2008 |
Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis.
Topics: Aged; Antifungal Agents; Fatal Outcome; Female; Fluconazole; Humans; Meningitis, Cryptococcal; Risk | 2008 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
Reversible visual disturbance due to cryptococcal uveitis in a non-HIV individual.
Topics: Antifungal Agents; Cerebrospinal Fluid Shunts; Cryptococcosis; Endophthalmitis; Fluconazole; HIV Ser | 2008 |
Successful lumbarperitoneal derivation during refractory intracranial pressure due to cryptococcal meningitis, in an HIV-negative patient.
Topics: Adolescent; Antifungal Agents; Cryptococcus neoformans; Fluconazole; HIV Seronegativity; Humans; Imm | 2008 |
Disseminated cryptococcal infection despite treatment for cryptococcal meningitis.
Topics: Adult; Amphotericin B; Cryptococcosis; Fatal Outcome; Fluconazole; HIV Seropositivity; Humans; Male; | 1995 |
[Severe pulmonary and meningeal cryptococcosis in an immunocompetent Cambodian].
Topics: Cambodia; Combined Modality Therapy; Cryptococcosis; Diagnosis, Differential; Fluconazole; Humans; I | 1995 |
Cryptococcosis, AIDS, and clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Cryptococcosis; Drug Resistance; Drug Therapy, C | 1995 |
Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients.
Topics: Adult; Case-Control Studies; CD4 Lymphocyte Count; Female; Fluconazole; HIV Infections; Humans; Male | 1995 |
[A case report: cryptococcal meningitis and fluconazole therapy].
Topics: Adolescent; Azathioprine; Female; Fluconazole; Humans; Immunocompromised Host; Lupus Erythematosus, | 1994 |
Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis.
Topics: Acquired Immunodeficiency Syndrome; Cryptococcus neoformans; Drug Resistance, Microbial; Fluconazole | 1994 |
[Clinical experience with fluconazole monotherapy in cryptococcal meningitis: report of four cases].
Topics: Adult; Aged; Drug Evaluation; Female; Fluconazole; Humans; Male; Meningitis, Cryptococcal; Middle Ag | 1993 |
HIV-negative "AIDS" in Kentucky: a case of idiopathic CD4+ lymphopenia and cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4 Antigens; Fluconazole; HIV Seronegativity; Humans; Ke | 1994 |
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Blotting, Southern; Cerebrospinal Fluid; Diagnosis, | 1993 |
Pyrolysis typing of isolates from a recurrence of systemic cryptococcosis.
Topics: Aged; Aneurysm; Asthma; Blood Vessel Prosthesis; Cryptococcosis; Cryptococcus neoformans; Diabetes M | 1994 |
Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptococcus neoformans; Drug Resistance, Microbial; F | 1993 |
Cryptococcal meningitis in Lilongwe and Blantyre, Malawi.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcus neoformans; Female; Fluco | 1994 |
[Clinical and pharmacokinetic observations on fluconazole in the management of cryptococcal meningitis].
Topics: Adult; AIDS-Related Opportunistic Infections; Biological Availability; Fluconazole; Humans; Male; Me | 1993 |
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcus neoformans; Drug Resistance, Mic | 1993 |
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Animals; Disease Models, Animal; Drug Resistance, Microbial; Flu | 1993 |
Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Case-Control Stud | 1995 |
Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome.
Topics: Animals; Antifungal Agents; Antigens, Fungal; Brain Edema; Cryptococcus neoformans; Drug Therapy, Co | 1996 |
Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcosis; Female; Fluconazole; France; HIV Ser | 1996 |
Clinical and laboratory features of cryptococcal meningitis in HIV-AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebrospinal Fluid; Cryptococcus neoforma | 1995 |
Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Base Sequence; Cryptococcus neoformans; DN | 1996 |
[A case of acquired immunodeficiency syndrome associated with cryptococcemia and cryptococcal meningitis].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Fluconazol | 1996 |
Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Clinical Trials as Topic; Cryptococ | 1996 |
Editorial response: management of cryptococcal meningitis--have we answered all the questions?
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; | 1996 |
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Topics: Amphotericin B; Animals; Antifungal Agents; Blood; Cryptococcus neoformans; Fluconazole; Humans; Itr | 1996 |
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Body Weight; Brain; Cryptococcus neoformans; Dose-Response Relationship, | 1996 |
Fluconazole monotherapy for cryptococcosis in non-AIDS patients.
Topics: Adult; Aged; Antifungal Agents; Antigens, Fungal; Cryptococcosis; Cryptococcus neoformans; Female; F | 1996 |
Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cryptococcus neoformans; Drug Resistance, Microbial; F | 1996 |
Fluconazole and amphotericin B for cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Female; Fluconazole; Humans; Me | 1996 |
[Systemic mycoses: therapy with a new antifungal drug diflucan].
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Fatal Outcome; Female; Fluconazole; | 1996 |
[Focusing on therapy of systemic mycoses].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Dose-Response | 1995 |
Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Brain; Cryptococcus neoformans; Disease Models, Animal; Dose-Response Re | 1997 |
Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.
Topics: Animals; Antifungal Agents; Body Weight; Cryptococcus neoformans; Disease Models, Animal; Drug Evalu | 1997 |
Amphotericin B with or without flucytosine followed by fluconazole as primary therapy for cryptococcal meningitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combinat | 1996 |
Favorable visual outcome in cryptococcal meningitis.
Topics: Acetazolamide; Adolescent; Anti-Inflammatory Agents; Antifungal Agents; Dexamethasone; Female; Fluco | 1997 |
Use of fluconazole in the treatment of non-AIDS cryptococcal meningitis.
Topics: Aged; Antifungal Agents; Diabetes Mellitus, Type 1; Fluconazole; Humans; Male; Meningitis, Cryptococ | 1997 |
Adverse reactions to fluconazole: illustrative case with focus on desensitization.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Desensitization, Immunologic; Drug | 1997 |
Treatment of cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 1997 |
Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis.
Topics: Amphotericin B; Animals; Body Weight; Brain; Drug Therapy, Combination; Fluconazole; Flucytosine; Ma | 1998 |
Fluconazole penetration into the prostatic fluid of patients with AIDS-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Body Fluids; Cryptococcus neoforman | 1998 |
Recurrent cryptococcal choroiditis in a renal transplant patient: clinicopathologic study.
Topics: Adult; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Choroiditis; Cryptococcosis; Cryptoco | 1998 |
Case report of long-term survival in a patient with acquired immunodeficiency syndrome and cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; An | 1998 |
Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Antifungal Agents; Cluster Analysis; Cryptococcus neoformans; DN | 1998 |
Risk factors for cryptococcal meningitis in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Case-Control Studies; Cerebrospinal | 1999 |
[Neurologic cryptococcosis: meningitis of the immunosuppressed patient].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antifungal Agen | 1999 |
Midbrain infarction: a rare presentation of cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Cerebral Infarction; Chronic Disease; Fluconazole; Humans; | 1999 |
Disseminated cutaneous sporotrichosis in an AIDS patient receiving maintenance therapy with fluconazole for previous cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Female; Fluconazole; Humans; Meningitis, | 1999 |
The prognostic factors of cryptococcal meningitis in HIV-negative patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Drug Therapy, Combina | 1999 |
Cryptococcal meningoencephalitis and sarcoidosis.
Topics: Adult; Antifungal Agents; Cryptococcus neoformans; Female; Fluconazole; Humans; Meningitis, Cryptoco | 1999 |
Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis.
Topics: Adult; Antifungal Agents; Cryptococcosis; Fluconazole; Humans; Lung Diseases, Fungal; Male; Meningit | 1999 |
Fluconazole-induced agranulocytosis with eosinophilia.
Topics: Aged; Agranulocytosis; Antifungal Agents; Eosinophilia; Fluconazole; Humans; Leukocyte Count; Male; | 2000 |
AIDS patients in South Africa to get free drug.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Industry; Fluconazole; Humans; Mening | 2000 |
Cryptococcal meningitis in acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Female; Fluconazole | 1999 |
Cryptococcal meningitis in non-HIV-infected patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; C | 2000 |
HIV/AIDS case histories: diagnostic problems. Cryptococcoma of the lung.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Autopsy; Fatal Outcome; Fluconazole | 1999 |
Case report. Granuloma caused by Cryptococcus neoformans.
Topics: Adult; Antifungal Agents; Brain; Cryptococcus neoformans; Fluconazole; Humans; Male; Meningitis, Cry | 2000 |
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746.
Topics: Animals; Antifungal Agents; Cryptococcus neoformans; Fluconazole; Meningitis, Cryptococcal; Mice; Mi | 2000 |
Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2000 |
AIDS and Africa.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Africa; AIDS Vaccines; Anti-HIV Agents; Antif | 2000 |
Fungal infection overview.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Blastomycosis; Candidiasis | 1995 |
Cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Fluconazol | 1996 |
Pfizer will donate Fluconazole to South Africa.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Drug Costs; Drug Industry; Fluconazole; Hu | 2000 |
Cryptococcal meningitis in renal transplant patients associated with environmental exposure.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Kidney Failure, Chronic; Kidney Transplantat | 1999 |
Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Chorioretinitis; Cr | 2001 |
Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Female; Fluconazo | 2001 |
[Cryptococcal meningitis in an immunocompetent patient: efficacy of fluconazole].
Topics: Adult; AIDS-Related Opportunistic Infections; Fluconazole; HIV Seropositivity; Humans; Immunocomprom | 1992 |
Nervous system cryptococcosis in the immunocompromised.
Topics: AIDS-Related Opportunistic Infections; Cryptococcus neoformans; Developing Countries; Fluconazole; H | 1992 |
Efficacy of oral fluconazole in Cryptococcus neoformans infection.
Topics: Administration, Oral; Adult; Cryptococcus neoformans; Fluconazole; Humans; Kidney Transplantation; M | 1992 |
Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Fluconazole; Humans; Meningitis, Cryptococcal | 1992 |
Cryptococcal meningitis in AIDS occurring despite systemic antifungal therapy.
Topics: Acquired Immunodeficiency Syndrome; Fluconazole; Humans; Ketoconazole; Meningitis, Cryptococcal | 1992 |
Does fluconazole prevent cryptococcal meningitis in human immunodeficiency virus-infected patients?
Topics: Adult; Case-Control Studies; Fluconazole; HIV Infections; Humans; Male; Meningitis, Cryptococcal; Re | 1992 |
Rapid relapse of cryptococcal meningitis after termination of maintenance fluconazole in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cryptococcus neoformans; Fluconazole; Follow-Up Studies; | 1992 |
[Fluconazole treatment of cryptococcal meningitis associated with HIV infection. Presentation of 4 cases].
Topics: Administration, Oral; Adult; Amphotericin B; Drug Therapy, Combination; Female; Fluconazole; Flucyto | 1992 |
Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) in African patients: treatment with fluconazole.
Topics: Acquired Immunodeficiency Syndrome; Drug Evaluation; Female; Fluconazole; Humans; Male; Meningitis, | 1992 |
Amphotericin versus fluconazole in cryptococcal meningitis.
Topics: Amphotericin B; Fluconazole; Humans; Kidney; Meningitis, Cryptococcal | 1992 |
Amphotericin versus fluconazole in cryptococcal meningitis.
Topics: Amphotericin B; Cerebrospinal Fluid; Cryptococcus; Fluconazole; Humans; Meningitis, Cryptococcal | 1992 |
Fluconazole: a position statement by the Society of Infectious Diseases Pharmacists.
Topics: Amphotericin B; Candidiasis; Drug Interactions; Fluconazole; Flucytosine; Humans; Meningitis, Crypto | 1992 |
[Cryptococcal meningitis in patients with AIDS: combined treatment with amphotericin B and fluconazole, and high levels of adenosine deaminase in cerebrospinal fluid].
Topics: Acquired Immunodeficiency Syndrome; Adenosine Deaminase; Adult; Amphotericin B; Drug Therapy, Combin | 1992 |
Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Fluconazole; Humans; Male; Meningit | 1992 |
[Cryptococcosis in AIDS patients: a study of 19 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Cryptococcosis; Cryptococcus neoformans; | 1992 |
Suppressive therapy for cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Fluconazole; Humans; Meningitis, Cryptococcal; R | 1992 |
Suppressive therapy for cryptococcal meningitis.
Topics: Amphotericin B; Drug Therapy, Combination; Fluconazole; Flucytosine; Humans; Meningitis, Cryptococca | 1992 |
Suppressive therapy for cryptococcal meningitis.
Topics: Amphotericin B; Fluconazole; Humans; Meningitis, Cryptococcal; Patient Dropouts; Research Design | 1992 |
Abdominal cyst formation following ventriculoperitoneal shunt in a case of hydrocephalus due to cryptococcal meningitis. Case report: completely cured by surgical removal of the cyst and treatment with a newly developed anti-fungal drug (Difulcan).
Topics: Cerebrospinal Fluid Shunts; Combined Modality Therapy; Cysts; Female; Fluconazole; Humans; Hydroceph | 1991 |
[Cryptococcal meningitis in AIDS: successful long-term prophylaxis with fluconazole].
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antigens, Bacterial; Cryptococcus; Drug T | 1991 |
Fluconazole well tolerated by AIDS patients with cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Fluconazole; Humans; Male; Meningitis, Cryptococcal | 1991 |